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INTRODUCTION
This dissertation deals with the studies carried out by the writer in this laboratory on the
development of bioanalytical method used for the study of validation parameters of selected
corticosteroids in rat plasma by RP-HPLC method.  Before discussing the experimental
results, a brief introduction to bioanalytical methods of analysis, biopharmaceutical analysis,
analysis of drugs in biological media, preliminary treatment of biological samples, estimation
procedures for drugs and metabolites from biological samples, estimation of drugs in
biological sample by RP-HPLC or LC-MS/MS methods.
1.1 Biopharmaceutical Analysis
1.1.1 Need for Biopharmaceutical Analysis
Methods for measurement of drugs in biological media are increasingly important problems
related to following studies which are highly dependent on biopharmaceutical analytical
methods.
 Bioavailability and Bioequivalence Studies
 New Drug Development
 Clinical Pharmacokinetics
 Research in Basic Biomedical and Pharmaceutical Sciences
 Therapeutic drug monitoring
1.1.2 Analysis of drugs in various biological media
The most common samples obtained for biopharmaceutical analysis are blood and urine.
Faeces are also utilized, especially if the drug or metabolite is poorly absorbed or extensively
excreted in the bile. Other media that can be utilized include saliva, breath, and tissue.
The choice of sampling media is determined largely by the nature of the drug study. For
example, drug levels in a clinical pharmacokinetic study demand the use of blood, urine, and
possibly saliva. A bioavailability study may require drug level data in blood and/or urine
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Whereas a drug identification or drug abuse problem may be solved with only one type of
biological sample.
Detection of a drug or its metabolite in biological media is usually complicated by the matrix.
Because of this, various types of cleanup procedures involving techniques such as solvent
extraction and chromatography are employed to effectively separate drug components from
endogenous biological material. The ultimate sensitivity and selectivity of the assay method
may be limited by the efficiency of the clean up methodology.
Whole blood is usually collected by venipuncture with either a hypodermic syringe or a
Vacutainers apparatus. The volume of blood collected at any one sampling time is usually
limited to 5 to 15 ml (depending on the assay sensitivity and the total number of samples
taken for a given study). If the blood is allowed to clot and is then centrifuged, about 30 to
50% of the original volume is collected as serum (upper level). Thus, plasma generally is
preferred because of its greater yield from blood. The greater the yield, the greater the
amount of drug and the fewer the problems with sensitivity. Blood, serum, or plasma samples
can be utilized for drug studies and may require protein denaturation steps before further
manipulation.
If plasma or serum is used for the analytical procedure, the fresh whole blood should be
centrifuged immediately at 3000rpm for approximately 5 to 10 min, and the supernatant
should be transferred by means of a suitable device, such as a Pasteur pipette, to a clean
container of appropriate size for storage. The remaining blood cells can then be discarded or
stored for further studies such as drug binding.
Urine is the easiest to obtain from the patient and also permits collection of large and
frequently more concentrated samples. The lack of protein in a healthy individual's urine
obviates the need for denaturation steps. Because urine samples are readily obtained and
often provide the greatest source of metabolites, they are frequently analyzed in drug
metabolism studies.
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Saliva and breath are biological media obtained from humans when constant ratio between
plasma and salivary levels of certain drugs exists via non invasive sampling techniques.
Saliva is advantageous in drug studies done with children. Although the concentrations of
drugs in saliva are rarely equal to those in plasma, a constant ratio (over an effective
therapeutic range) permits calculation of plasma levels based on salivary analysis.
Separation or isolation of drugs and metabolites from biological samples is performed in
order to partially purify a sample. In this manner, an analyst can obtain the selectivity and
sensitivity needed to detect a particular compound and can do so with minimum interference
from components of the more complex biological matrix. The number of steps in a separation
procedure should be kept to a minimum to prevent loss of drug or metabolite. Sometimes, the
separation steps are preceded by a sample pretreatment.
1.1.3 Storage requirements for biological samples
In order to avoid decomposition or other potential chemical changes in the drugs to be
analyzed, biological samples should be frozen immediately upon collection and thawed
before analysis. When drugs are susceptible to plasma esterase, the addition of esterase
inhibitors, such as sodium fluoride, to blood samples immediately after collection helps to
prevent drug decomposition.
When collecting and storing biological samples, the analyst should be aware of facts that from tubing
or storage vessels that can contaminate the sample. For example, plastic ware frequently contains the
high boiling liquid bis (2-ethylhexyl) phthalate; similarly, the plunger plugs of Vacutainers are known
to contain tri-butoxyethyl phosphate, which can interfere in certain drug analysis.
1.1.4 Bioavailability studies
Bioavailability is defined as "the rate and extent to which the active ingredient or active
moiety is absorbed from a drug product and becomes available at the site of action. For drug
products that are not intended to be absorbed into the bloodstream, bioavailability may be
assessed by measurements intended to reflect the rate and extent to which the active
ingredient or active moiety becomes available at the site of action." This definition focuses on
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the processes by which the active ingredients or moieties are released from an oral dosage
form and move to the site of action.
BA studies provide pharmacokinetic information related to distribution, elimination, the
effects of nutrients on absorption of the drug, dose proportionality, linearity in
pharmacokinetics of the active moieties and, where appropriate, inactive moieties.
BA data may also provide information indirectly about the properties of a drug substance
prior to entry into the systemic circulation, such as permeability and the influence of pre
systemic enzymes and/or transporters (e.g., p-glycoprotein).
1.1.5 Preliminary treatment of biological fluids
In most cases, preliminary treatment of a sample is needed before the analyst can proceed to
the measurement step. Analyses are required for drug in samples as diverse as plasma, urine,
feces, saliva, bile, sweat, and seminal fluid. Each of these samples has its own set of factors
that must be considered before an appropriate pretreatment method can be selected. Such
factors as texture and chemical composition of the sample, degree of drug-protein binding,
chemical stability of the drug, and types of interferences can affect the final measurement
step.
1.1.6 Extraction procedures for biological fluids and samples
After pre treating biological material, the next step is usually the extraction of the drugs from
the biological matrix. All separation procedures use one or more treatments of matrix-
containing solute with some fluid. If the components are a liquid (extracting solvents) and a
solid (e.g., lyophilized feces), it is an example of liquid-solid extraction. If the extraction
involves two liquid phases, it is an example of liquid-liquid extraction.
1.1.7 Liquid-Solid extraction (Solid phase extraction)
Liquid - solid extractions occur between a solid phase and a liquid phase, either phase may
initially contain the drug substance. Among the solids that have been used successfully in the
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extraction (usually via adsorption) of drugs from liquid samples are XAD-2 resin, charcoal,
alumina, silica gel, and aluminum silicate. Sometimes the drugs are contained in a solid
phase, such as in lyophilized specimens. Liquid-solid extraction is often particularly suitable
for polar compounds that would otherwise tend to remain in the aqueous phase. The method
could also be useful for amphoteric compounds that cannot be extracted easily from water.
Factors governing the adsorption and elution of drugs from the resin column include solvent
polarity; flow rate of the solvent through the column, and the degree of contact the solvent
has with the resin beads. In the adsorption process, the hydrophobic portion of the solute that
has little affinity for the water phase is preferentially adsorbed on the resin surface while the
hydrophilic portion of the solute remains in the aqueous phase. Alteration in the lipophilic /
hydrophilic balance within the solute or solvent mix, and not within the resin, affects
adsorption of the solute.
Biological samples can be prepared for cleanup by passing the sample through the resin bed
where drug (metabolite) components are adsorbed and finally eluted with an appropriate
solvent. The liquid solid extraction method provides a convenient isolation procedure for blood
samples, thus avoiding solvent extraction, protein precipitation, drug losses, and emulsion
formulation. It is possible; however, that strong drug-protein binding could prevent sufficient
adsorption of the drug to resin.
1.1.8 Liquid-liquid extraction
Liquid-liquid extraction is probably the most widely used technique because
 The analyst can remove a drug or metabolite from larger concentrations of
endogenous materials that might interfere with the final analytical determination.
 The technique is simple, rapid, and has a relatively small cost factor per sample.
 The extract containing the drug can be evaporated to dryness, and the residue can be
redissolved in a smaller volume of a more appropriate solvent. In this manner, the
sample becomes more compatible with a particular analytical methodology in the
measurement step, such as a mobile phase in HPLC determinations.
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 The extracted material can be redissolved in small volumes (e.g., 100 to 500 l of
solvent), thereby extending the sensitivity limits of an assay.
 It is possible to extract more than one sample concurrently.
 Near quantitative recoveries (90% or better) of most drugs can be obtained through
multiple or continuous extractions.
1.2 Method Development
Method development involves considerable trial and error procedures. In general, one begins
with reversed phase chromatography, when the compounds are hydrophilic in nature with
many polar groups and are water-soluble.
The pH of the mobile phase has to be selected in such a way that the compounds are not
ionized. If the retention times are too short, then decrease 5 % of the organic phase
concentration in the mobile phase, if the retention times are too long, an increase 5% of
organic phase concentration in the mobile phase is needed.
Elution of drug molecules can be altered by changing the polarity of the mobile phase. The
elution strength of a mobile phase depends upon its polarity. Ionic samples (acidic or basic)
can be separated only, if they are present in undissociated form. Dissociation of ionic samples
may be suppressed by proper selection of pH. Whenever acidic or basic samples are to be
separated it is strongly advisable to control mobile phase pH by adding a buffer. PH of the
buffer is to be adjusted before adding organic phase. The buffer selected for a particular
separation should be used to control pH over the range of pka ±1.0.
Optimizations can be started only after a reasonable chromatogram has been obtained. A
reasonable chromatogram means that all the compounds are detected by more or less
symmetrical peaks on the chromatogram.
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During method development selection of column can be streamlined by starting with shorter
columns (50 mm, 100 mm or even 150 mm). By selecting a shorter column with an
appropriate phase the run time can be minimized so that an elution order and an optimum
mobile phase can be quickly determined. The internal diameter of the column is also one
factor is to be considered. Many laboratories use 4.6 mm ID as standard one, but it is worth
considering to use 4mm ID column as an alternative. This 4 mm column requires only 75 %
of the solvent consumption than that of 4.6 mm column.
Selecting an appropriate stationary phase can also help to improve the efficiency of method
development. For example, a C-8 phase (reversed phase) can provide a further time saving
over a C-18 as it does not retain the analytes as strongly as the C-18 phase. For normal phase
application Cyano phases are most versatile. C-18 (250 x 4.6 mm) column are more often
used in laboratory. These columns are able to resolve a wide variety of compounds due to
their selectivity and higher number of theoretical plates.
Selection of internal standard should be on the basis of structural similarity, physicochemical
properties related to the analyte to be quantified. Method optimization or Performance of
selected method is checked by running three or more precision and accuracy batches and
evaluating the results for meeting acceptance criteria for within run precision, accuracy and
between run precision and accuracy. Finally selected method has to be validated to see
whether it does what it was intended to do; i.e. it must be validated through validation
parameters.
1.3 Bio-Analytical Method Validation
1.3.1 Principles of Bioanalytical Method Validation and Establishment
 The fundamental parameters to ensure the acceptability of the performance of a
bioanalytical method validation are accuracy, precision, selectivity, sensitivity,
reproducibility, and stability.
 A specific, detailed description of the bioanalytical method should be written. This
can be in the form of a protocol, study plan, report, and/or SOP.
Introduction
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 8
 Each step in the method should be investigated to determine the extent to which
environmental, matrix, material, or procedural variables can affect the estimation of
analyte in the matrix from the time of collection of the material up to and including
the time of analysis.
 It may be important to consider the variability of the matrix due to the physiological
nature of the sample. In the case of LC-MS-MS-based procedures, appropriate steps
should be taken to ensure the lack of matrix effects throughout the application of the
method, especially if the nature of the matrix changes from the matrix used during
method validation.
 A bioanalytical method should be validated for the intended use or application. All
experiments used to make claims or draw conclusions about the validity of the
method should be presented in a report (method validation report).
 Whenever possible, the same biological matrix as the matrix in the intended samples
should be used for validation purposes. (For tissues of limited availability, such as
bone marrow, physiologically appropriate proxy matrices can be substituted.)
 The stability of the analyte (drug and/or metabolite) in the matrix during the
collection process and the sample storage period should be assessed, preferably prior
to sample analysis.
 For compounds with potentially labile metabolites, the stability of analyte in matrix
from dosed subjects (or species) should be confirmed.
 The accuracy, precision, reproducibility, response function, and selectivity of the
method for endogenous substances, metabolites, and known degradation products
should be established for the biological matrix. For selectivity, there should be
evidence that the substance being quantified is the intended analyte.
 The concentration range over which the analyte will be determined should be defined
in the bioanalytical method, based on evaluation of actual standard samples over the
range, including their statistical variation. This defines the standard curve.
 A sufficient number of standards should be used to adequately define the relationship
between concentration and response. The relationship between response and
concentration should be demonstrated to be continuous and reproducible. The number
of standards used should be a function of the dynamic range and nature of the
concentration-response relationship. In many cases, six to eight concentrations
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(excluding blank values) can define the standard curve. More standard concentrations
may be recommended for nonlinear than for linear relationships.
 The ability to dilute samples originally above the upper limit of the standard curve
should be demonstrated by accuracy and precision parameters in the validation.
1.4 VALIDATION
1.4.1 Types of validation process
A. Full validation
Full validation is important when developing and implementing a bioanalytical method for
first time. Full validation is important for a new drug entity. A full validation of the revised
assay is important if metabolites are added to an existing assay for quantification.
B. Partial validation
Partial validations are modifications of already validated bioanalytical methods. Partial
validation can range from as little as one intra-assay accuracy and precision determination to
a nearly full validation.
C. Cross-validation
Cross-validation is a comparison of validation parameters when two or more bioanalytical
methods are used to generate data within the same study or across different studies. An
example of cross validation would be a situation where an original validated bioanalytical
method serves as the reference and the revised bioanalytical method is the comparator. The
comparisons should be done both ways.
1.5 VALIDATION PARAMETERS
1.5.1 Linearity
Linearity assesses the ability of the method to obtain test results that are directly proportional
to the concentration of the analyte in the sample. The linear range of the method must be
determined regardless of the phase of drug development. ICH guidelines recommend
evaluating a minimum of five concentrations to assess linearity. The five concentration levels
should bracket the upper and lower concentration levels evaluated during the accuracy study.
A calibration (standard) curve is the relationship between instrument response and known
concentrations of the analyte. A calibration curve should be generated for each analyte in the
(accountability systems that ensure integrity of test articles), sample preparation and
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analyticalal tools such as methods, reagents, equipments, instrumentation and procedures for
quality control and verification of results.
The obtained values of slope a and intercept b is used in the Linear regression equation:
y = ax + b
1.5.2 Calibration/Standard Curve
A calibration (standard) curve is the relationship between instrument response and known
concentrations of the analyte. A calibration curve should be generated for each analyte in the
6 sample. A sufficient number of standards should be used to adequately define the
relationship between concentration and response. A calibration curve should be prepared in
the same biological matrix as the samples in the intended study by spiking the matrix with
known concentrations of the analyte. The number of standards used in constructing a
calibration curve will be a function of the anticipated range of analytical values and the
nature of the analyte/response relationship. Concentrations of standards should be chosen on
the basis of the concentration range expected in a particular study. A calibration curve should
consist of a blank sample (matrix sample processed without internal standard), a zero sample
(matrix sample processed with internal standard), and six to eight non-zero samples covering
the expected range, including LLOQ.
 Lower Limit of Quantification (LLOQ)
The lowest standard on the calibration curve should be accepted as the limit of quantification
if the following conditions are met: C The analyte response at the LLOQ should be at least 5
times the response compared to blank response. C Analyte peak (response) should be
identifiable, discrete, and reproducible with a precision of 20% and accuracy of 80-120%.
1.5.3 Selectivity (Specificity)
Selectivity is the ability of an analytical method to differentiate and quantify the analyte in
the presence of other components in the sample. For selectivity, analysis of blank samples of
the appropriate biological matrix (plasma, urine, or other matrix) should be obtained from at
least five to six sources. Each blank sample should be tested for interference and selectivity
should be ensured at the lower limit of quantification (LLOQ). Potential interfering
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substances in a biological matrix include endogenous matrix components, metabolites,
decomposition products, and in the actual study, concomitant medication and other
exogenous xenobiotics. If the method is intended to quantify more than one analyte, each
analyte should be tested to ensure that there is no interference.
 For every phase of product development, the analytical method must demonstrate
specificity. The method must have the ability to unambiguously assess the analyte of
interest while in the presence of all expected components, which may consist of
degradants, excipients/sample matrix, and sample blank peaks. The sample blank
peaks may be attributed to things such as reagents or filters used during the sample
preparation.
 For identification tests, discrimination of the method should be demonstrated by
obtaining positive results for samples containing the analyte and negative results for
samples not containing the analyte.
 For assay/related substances methods, the active peak should be adequately resolved
from all impurity/degradant peaks, placebo peaks, and sample blank peaks.
 The forced degradation studies should consist of exposing the API and finished
product to acid, base, peroxide, heat, and light conditions, until adequate degradation
of the active has been achieved. An acceptable range of degradation may be 10–30%
but may vary based on the active being degraded. Overdegradation of the active
should be avoided to prevent the formation of secondary degradants.
 The selectivity is defined as the lack of significant interfering peaks at the retention
time of analyte and internal standard.
 Selectivity is evaluated by injecting extracted blank plasma samples (anticoagulant
sodium citrate) and comparing any interference with the response of the extracted
LOQ samples processed with internal standard.
1.5.4 Accuracy
Accuracy should be performed at a minimum of three concentration levels. For drug
substance, accuracy can be inferred from generating acceptable results for precision, linearity,
and specificity.
 For assay methods, the spiked placebo samples should be prepared in triplicate at 80,
100, and 120%. The weight of drug product may be varied in the sample preparation
step of the analytical method to prepare samples at the three levels listed above. In
this case, the accuracy study can be combined with method precision, where six
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sample preparations are prepared at the 100% level, while both the 80 and 120%
levels are prepared in triplicate.
 For assay methods, the change in active content must be controlled tightly to
establish sample stability. If impurities are to be monitored in the method sample,
solutions can be analyzed on multiple days and the change in impurity profiles can be
monitored.
 For chromatographic robustness, all compounds of interest, including placebo related
and sample blank components, should be present when evaluating the effect of
modifying chromatographic parameters. For an HPLC impurity method, this may
include a sample preparation spiked with available known impurities at their
specification level or, alternatively, a forced degraded sample solution can be
utilized. The analytical method should be updated to include defined stability of
solutions at evaluated storage conditions and any information regarding sample
preparation and chromatographic parameters, which need to be tightly controlled.
Sample preparation and chromatographic robustness may also be evaluated during
method development.
 The accuracy of an analyticalal method describes the closeness of mean test results
obtained by the method to the true value (concentration) of the analyte.Accuracy
should be measured using a minimum of five determinations per concentration.
The mean value should be within 15% of the actual value except, at LLOQ where it should
not deviate by more than 20 %. The deviation of the mean from the true value serves as the
measures of accuracy.
Mean Concentration
Nominal Concentration
1.5.5 Precision and repeatability
Repeatability reflects the closeness of agreement of a series of measurements under the same
operating conditions over a short interval of time. For a chromatographic method,
repeatability can be evaluated by performing a minimum of six replicate injections of a single
sample solution prepared at the 100% test concentration.
[%] Nominal = 100 x
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 Alternatively, repeatability can be determined by evaluating the precision from a
minimum of nine determinations that encompass the specified range of the method.
The nine determinations may be composed of triplicate determinations at each of
three different concentration levels, one of which would represent the 100% test
concentration.
 Intermediate precision reflects within laboratory variations such as different days,
different analysts, and different equipments. Intermediate precision testing can consist
of two different analysts, each preparing a total of six sample preparations, as per the
analytical method. The analysts execute their testing on different days using separate
instruments and analytical columns.
 The use of experimental design for this study could be advantageous because
statistical evaluation of the resulting data could identify testing parameters (i.e., brand
of HPLC system) that would need to be tightly controlled or specifically addressed in
the analytical method. Results from each analyst should be evaluated to ensure a level
of agreement between the two sets of data. Acceptance criteria for intermediate
precision are dependent on the type of testing being performed.
 However, precision testing should be conducted by one analyst for early phase
method qualification. Reproducibility reflects the precision between analytical testing
sites. Each testing site can prepare a total of six sample preparations, as per the
analytical method. Results are evaluated to ensure statistical equivalence among
various testing sites. Acceptance criteria similar to those applied to intermediate
precision also apply to reproducibility.
 Repeatability expresses the precision under the same operating conditions over a short
interval of time. Repeatability is also termed intraassay precision. Repeatability is
sometimes also termed within run or within day precision.
 The precision of an analytical method describes the closeness of individual measures
of an analyte when the procedure is applied repeatedly to multiple aliquots of a single
homogeneous volume of biological matrix.Precision should be measured using a
minimum of five determinations per concentration.
The precision determined at each concentration level should not exceed 15 % of the
Coefficient of variation (CV), except for the LLOQ where it should not exceed 20 % of the
coefficient of variation.
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[%] CV = 100 × standard deviation / Mean concentration
Good precision and accuracy can be obtained from methods with moderate recoveries,
provided they have adequate sensitivity.
1.5.6 Reproducibility
Reproducibility expresses the precision between laboratories (collaborative studies, usually
applied to standardization of methodology). Reproducibility only has to be studied, if a
method is supposed to be used in different laboratories. Unfortunately, some authors also
used the term reproducibility for within laboratory studies at the level of intermediate
precision. This should, however, be avoided in order to prevent confusion. As already
mentioned above, precision and bias can be estimated from the analysis of QC samples under
specified conditions. As both precision and bias can vary substantially over the calibration
range, it is necessary to evaluate these parameters at least at three concentration levels (low,
medium, high).
1.5.7 Stability
Drug stability in a biological fluid is a function of the storage conditions, the chemical
properties of the drug, the matrix, and the container system. The stability of an analyte in a
particular matrix and container system is relevant only to that matrix and container system
and should not be extrapolated to other matrices and container systems. Stability procedures
should evaluate the stability of the analytes during sample collection and handling, after long-
term (frozen at the 7 intended storage temperature) and short-term (bench top, room
temperature) storage, and after going through freeze and thaw cycles and the analytical
process. Conditions used in stability experiments should reflect situations likely to be
encountered during actual sample handling and analysis. The procedure should also include
an evaluation of analyte stability in stock solution.
 Freeze and Thaw Stability
Analyte stability should be determined after three freeze and thaw cycles. At least three
aliquots at each of the low and high concentrations should be stored at the intended storage
temperature for 24 hours and thawed unassisted at room temperature. When completely
thawed, the samples should be refrozen for 12 to 24 hours under the same conditions. The
freeze–thaw cycle should be repeated two more times,then analyzed on the third cycle. If an
analyte is unstable at the intended storage temperature, the stability sample should be frozen
at -700C during the three freeze and thaw cycles.
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 Short-Term Temperature Stability
Three aliquots of each of the low and high concentrations should be thawed at room
temperature and kept at this temperature from 4 to 24 hours (based on the expected duration
that samples will be maintained at room temperature in the intended study) and analyzed.
 Long-Term Stability
The storage time in a long-term stability evaluation should exceed the time between the date
of first sample collection and the date of last sample analysis. Long-term stability should be
determined by storing at least three aliquots of each of the low and high concentrations under
the same conditions as the study samples. The volume of samples should be sufficient for
analysis on three separate occasions. The concentrations of all the stability samples should be
compared to the mean of back-calculated values for the standards at the appropriate
concentrations from the first day of long-term stability testing.
 Stock Solution Stability
The stability of stock solutions of drug and the internal standard should be evaluated at room
temperature for at least 6 hours. If the stock solutions are refrigerated or frozen it for the
relevant period, the stability should be documented. After completion of the desired storage
time, the stability should be tested by comparing the instrument response with that of freshly
prepared solutions.
 Post-Preparative Stability
The stability of processed samples, including the resident time in the autosampler, should be
determined. The stability of the drug and the internal standard should be assessed over the
anticipated run time for the batch size in validation samples by determining concentrations on
the basis of original calibration standards.
1.5.8 Recovery
As already mentioned above, recovery is not among the validation parameters regarded as
essential by the Conference Reports. Most authors agree that the value for recovery is not
important as long as the data for LLOQ, LOD, precision and accuracy (bias) are acceptable. It
can be calculated by comparison of the analyte response after sample workup with the
response of a solution containing the analyte at the theoretical maximum concentration.
Therefore, absolute recoveries can usually not be determined if the sample workup includes a
derivatization step, as the derivatives are usually not available as reference substances.
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 The recovery of an analyte in assay is the detector response obtained from an amount
of the analyte added and extracted from the biological matrix, compared to the pure
authentic standard. Recovery pertains to the extraction efficiency of an analyticalal
method within the limits of variability.
 Recovery of the analyte need not be 100%, but the extent of recovery of an analyte
and of the internal standard should be consistent, precise and reproducible.Recovery
experiments should be performed by comparing the analyticalal results for extracted
samples at three concentrations (low, medium and high) with unextracted standards
that represent 100% recovery.
[%] Recovery   = 100 x
Mean Response of Extracted Samples
Mean Response of Post Extracted Standards
1.6 Application of Validated Method to Routine Drug Analysis
Assays of all samples of an analyte in a biological matrix should be completed within the
time period for which stability data are available. In general, biological samples can be
analyzed with a single determination without duplicate or replicate analysis if the assay
method has acceptable variability as defined by validation data. This is true for procedures
where precision and accuracy variabilities routinely fall within acceptable tolerance limits.
For a difficult procedure with a labile analyte where high precision and accuracy
specifications may be difficult to achieve, duplicate or even triplicate analyses can be
performed for a better estimate of analyte. A calibration curve should be generated for each
analyte to assay samples in each analytical run and should be used to calculate the
concentration of the analyte in the unknown samples in the run.
The following recommendations should be noted in applying a bioanalytical method to
routine drug analysis:
 A matrix-based standard curve should consist of a minimum of six standard points,
excluding blanks (either single or replicate), covering the entire range.
 Response Function: Typically, the same curve fitting, weighting, and goodness of fit
determined during prestudy validation should be used for the standard curve within
the study. Response function is determined by appropriate statistical tests based on the
actual standard points during each run in the validation. Changes in the response
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function relationship between prestudy validation and routine run validation indicate
potential problems.
 The QC samples should be used to accept or reject the run. These QC samples are
matrix spiked with analyte.
 System suitability: Based on the analyte and technique, a specific SOP (or sample)
should be identified to ensure optimum operation of the system used. Any required
sample dilutions should use like matrix (e.g., human to human) obviating the need to
incorporate actual within-study dilution matrix QC samples.
 Repeat Analysis: It is important to establish an SOP or guideline for repeat analysis
and acceptance criteria. This SOP or guideline should explain the reasons for
repeating sample analysis. Reasons for repeat analyses could include repeat analysis
of clinical or preclinical samples for regulatory purposes, inconsistent replicate
analysis, samples outside of the assay range, sample processing errors, equipment
failure, poor chromatography, and inconsistent pharmacokinetic data. Reassays
should be done in triplicate if sample volume allows. The rationale for the repeat
analysis and the reporting of the repeat analysis should be clearly documented.
1.7 Analytical Techniques in Bioanalysis
Chromatography is a separation technique by which solutes of two or more components are
separated by a dynamic differential migrational process. In a system consisting of two phases,
one of which moves continuously in a given direction and in which individual components
exhibit differential mobility due to difference in their adsorption or partition or molecular size
etc. Methods for separation of Drugs and their metabolites in biological sample can be
developed, provided one has knowledge about the nature of the Drug, its molecular weight,
polarity, pKa, ionic character and the solubility parameter. An exact recipe for HPLC,
however, cannot be provided because method development involves considerable trial and
error procedures. The most difficult problem usually is where to start, what type of column to
be used with what kind of mobile phase.
Interfacing mass spectrometers with chromatographic separation techniques is one of the
most sophisticated and sensitive technique used in detection and quantization of Drug and its
active metabolite in biological fluid.
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Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 18
1.7.1 Selection of Mobile Phase
Since mobile phase governs solute –stationary phase interaction
 Practical considerations dictate that it should not degrade the equipment or column
packing .So strong acids; bases and halides should be avoided.
 Chemical purity of sample is important factor. Since large volume of solvents are
pumped through the column. Trace amount of impurities can easily concentrate in
column and eventually detrimental to the result. So HPLC grade solvents only
recommended to use in the analysis
 Volatility should be considered if sample recovery is required and mass transfer
between solvent and stationary phase will be reduced. Water, acetonitrile, ethanol, 2
propanol & methanol are widely used solvents.
1.7.2 Role of solvent type
Chromatographic separations thus vary with solvent properties and are related to sample
solubility, polarity and solvent strength. Solvents that interact strongly with the sample will
increase the sample ion exit in the solvents and are not able to equilibrate with adsorbent
surface. Changing the organic solvent will change the selectivity. In reverse phase, less polar
solvent exhibit greater solvent strength than polar solvents .The solvents water (most polar),
methanol, Acetonitrile and Tetrahydrofuran placed in ascending order of their polarity.
1.7.3 Selection of buffer and role of pH
pH is another factor in resolution equation that will affect the selectivity of the  separation. In
reverse phase HPLC, sample retention increases when the analyte is more hydrophobic .Thus
when an acid (HA) or base (B) is ionized (converted in the form of unionized free or base) it
becomes more hydrophilic and is less interactive with column binding sites.
Thus when selecting a buffer for a given application the following considerations are
important. They are,
 The buffer capacity is dependent on the buffer pH, pKa and buffer concentration.
 Other properties such as volatility, solubility, stability of the buffer and its reactivity
to the analytes play important role in chromatographic system.
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1.7.4 Selection of column
HPLC column is the important tool for separation of analytes .So the column must posses
good selectivity, efficiency and reproducibility to provide good separation of analytes.
Commonly used column are C-18, C-8, Phenyl, Cyano columns. They are chemically
different bonded phase having different selectivity with same mobile phase.
1.8 Chromatographic Method
The presence of metabolites or more than one drug in a biological sample usually demands a
more sophisticated separation for their measurement especially, when two or more drugs are
of similar physical and chemical nature. Chromatography is a separation technique that is
based on differing affinities of a mixture of solutes between at least two phases. The result is
a physical separation of the mixture into its various components. The affinities or interactions
can be classified in terms of a solute adhering to the surface of a polar solid (adsorption), a
solute dissolving in a liquid (partition), and a solute passing through or impeded by a porous
substance based on its molecular size (exclusion).
In the following sections, individual chromatographic techniques are discussed in relation to
their usefulness as separation tools for drugs or metabolites in biological samples.
1.9 High Performance Liquid Chromatography
HPLC is the chemistry based tool for quantifying and analyzing mixtures of chemical
compounds. It is used to find the amount of a chemical compound of interest within a mixture
of other chemicals. As the mobile phase used to separate the sample components is liquid
(like water or alcohol), thus the technique is termed Liquid chromatography. Due to the use
of reduced particle size (generally 5 µ) and closed packing of the adsorbent, a very high
pressure of about 6000 psi (400 atm) is required to force the mobile phase through the
column improving the performance of the instrument thus earning the name High Pressure/
Performance Liquid Chromatography.
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1.9.1 Basic principle of HPLC
High performance liquid chromatography (HPLC) is a separation technique which is utilizing
to differences in distribution of compounds in two phases called the stationary phase and the
mobile phase. The stationary phase is a thin layer created on the surface of fine particles and
the mobile phase is the liquid flowing over the particles. Under a certain dynamic condition,
each component in a sample has a different distribution equilibrium depending upon the
solubility in the phases and/ or molecular size. As a result, the components move at different
speeds over the stationary phase and are thereby separated from each other. The column is a
stainless steel (or resin) tube, which is packed with spherical solid particles. Mobile phase is
constantly fed into the column inlet at a constant rate by a pump. The sample injected from a
sample injector that are located near the column inlet. The injected sample enters the column
with the mobile phase and the components in the sample migrate through it, passing between
the stationary and the mobile phases. Compounds move in the column only when they are in
the mobile phase. Compounds that are tending to be distributed in the mobile phase therefore
migrate faster through the column while compounds that tend to be distributed in the
stationary phase migrate slower. In this way, each component is separated on the column and
sequentially elutes from the outlet. Each compound eluting from the column is detected by a
detector connected to the outlet of the column. The separation process is monitored by the
integrator from the time of injection to its elution, a graph is obtained. This graph is called a
chromatogram.
1.9.2 Elution Process
There are two modes of elution processes: Isocratic elution and Gradient elution.
1.9.2.1 Isocratic Elution
In an isocratic elution, a sample is injected onto a given column and the mobile phase
composition remains unchanged through the time required for the sample components to
elute from the column. No single isocratic elution can separate a complex mixture with
adequate resolution in a reasonable time and with good detectibility. The isocratic separation
of samples with widely varying k (partition ratio) values typically exhibits poor resolution of
early-eluting bands, difficult detection of late-eluting bands, and unnecessarily long elution
times.
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Figure 1 Isocratic LC System
1.9.2.2 Gradient Elution
Solvent Programming, also called gradient elution, involves changing the mobile-phase
composition either stepwise or continuously as elution proceeds during the chromatographic
run. The main purpose of gradient elution is to move strongly retained components of the
mixture faster, but having the least retained component well resolved. Usually all the sample
components are initially retained at the top of the column. Starting with the low content of the
organic component in the eluent, the least retained componentgets separated. Strongly
retained components will sit on the adsorbent surface on the top of the column, or will move
very slowly.
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Figure: 2 High-Pressure-Gradient Systems
1.9.3 The general instrumentation for HPLC incorporates the following components
 There is a solvent reservoir for the mobile phase.
 The mobile phase must be delivered to the column by different types of pump. To obtain
separations either based on short analysis time or under optimum pressure, a wide range
of pressure and flow is desirable. The pumping system must be pulse-free or else have
pulse damper to avoid generating baseline instability in the detector.
 Sampling valves or loops are used to inject the sample in the flowing mobile phase just
at the head of the separation column. Samples should be dissolved in a portion of the
mobile phase to eliminate an unnecessary peak.
 At the head of separation column there may be a guard column or an in-line filter to
prevent contamination of the main column by small particulate.
 To measure column inlet pressure, a pressure gauge is inserted in front of the separation
column.
 The separating column contains the packing needed to accomplish the desired HPLC
separation. These packings may be of silica for adsorption chromatography, bonded
phases for liquid-liquid chromatography, ion-exchange functional groups bonded to the
stationary support for ion-exchange chromatography, gels of specific porosity for
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exclusion chromatography, or some other unique packing for a particular separation
method.
 A detector with different type of data handling device completes the basic
instrumentation.5
Figure 3 Schematic Diagram of HPLC Instrument
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Figure 4 A Typical HPLC [Waters Alliance] System
1.9.4 Mobile –Phase Delivery System (Pumps)
The mobile phase must be delivered to the column over a wide range of flow rates and
pressure. A degasser is needed to remove dissolved air and other gases from the solvent.
Another desirable feature in the solvent-delivery system is the capability for generating a
solvent gradient. A pump should be able to operate at least 100 atm (1500 psi), a pressure
suited to less expensive chromatographs. However, 400 atm (6000 psi) is a more desirable
pressure limit. For many analytical columns only moderate flow rates of 0.5-2.0 ml/min need
to be generated.
There are two groups according to the manner in which they Works:
1.9.4.1 Constant flow rate pumps:
The two types of pumps in this category they are the reciprocating piston pump and syringe
drive pumps. The reciprocating piston pump is the most widely used pump in modern HPLC.
A filling and pumping cycle characterize this pump. During the filling cycle a piston is
withdrawn from a syringe chamber. Two check valves are connected to this chamber such
that during the piston withdrawal, solvent flows from the solvent reservoir but not into the
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pump outlet. When the piston direction is reversed, the check valves operate to allow solvent
to flow from the outlet valve only.
e.g. Milton Roy Reciprocating Pump, Dual Piston Pump, Triple Piston Pumps.
The syringe drive pump is a constant displacement pump in which all of the mobile phase
contained within the pump. It is, in effect, a single stroke displacement pump. A screw free
drive connected to a stepping motor actuates the piston inside the chamber. The voltage input
to the stepping motor controls the volume displaced by the pump per unit time. This type
pump produces a pulse less flow and requires no check valves.
1.9.4.2 Constant pressure pumps:
Constant pressure pump can deliver a constant-flow- rate if it operates against a constant
column backpressure and if the viscosity of mobile phase remains constant. Consequently
temperature should be controlled. Since the mobile phase is in direct contact with the
pressurized gas a significant amount of gas may be dissolved. Thus a piston of mobile phase
may contain sufficient dissolved gases to produce bubble in the detector. The pneumatic
amplifier pump (e.g. The Haskell Pump) is a modification of a simple gas displacement
pump. The gas pressure is applied to a large piston that is connected to a smaller diameter
piston in contact with the mobile phase. The pressure on the gas piston is translated to a
higher pressure (per unit area) on the solvent.6
1.9.5 Columns
The column is the heart of HPLC instrument. Columns are constructed of heavy-wall, glass-
lined metal tubing or stainless steel tubing to withstand high pressures (up to 680 atm) and
the chemical action of the mobile phase. Column end fittings and connector must be designed
with zero void volume to avoid unswept corners or stagnant pockets of mobile phase that can
contribute significantly to extra-column band broadening. Most column lengths range from
10 to 30 cm short, fast columns is 3 to 8 cm long. For exclusion chromatography, columns
are 50 to 100 cm long.
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1.9.6 Standard columns
Many HPLC separations are done on columns with an internal diameter of 4 to 5 mm. Such
columns provide a good compromise between efficiency, sample capacity, and the amount of
packing and solvent required. Column packing feature particles those are uniformly sized and
mechanically stable. Particle diameters lie in the range 3-5 µm, occasionally up to 10 µm or
higher for preparative chromatography. The columns are classified into various categories
depending on their carbon loading.
The various column parameters to be considered are:
 Column length
 Column internal diameter
 Particle shape
 Particle shape
 Pore size
 Surface area
 End capping
 Carbon load
Figure: 1.5- HPLC Column Dimensions
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Figure: 1.6-Column Hardware Examples
1.9.7 Detector
The choice of detector is an important consideration. There is little use in running a
separation if the detector one uses cannot see all the components of interest, or conversely, if
it sees too much. The sensitivity of universal detector for HPLC has not been devised yet.
Thus it is necessary to select a detector on the basis of compound under consideration, 7
Table: 1 List of detector
Detectors Analytes SolventRequirement Comments
UV-Visible With any
chromophore
UV-grade non-UV
absorbing solvents
Has a high degree of
selectivity & is useful for
many HPLC application
Fluorescence Fluorescent
compounds
UV grade non UV
absorbing solvents
Highly selective and
sensitive. Often used to
analyze derivatized
compounds
Refractive
Index (RI)
Compounds with
different RI to the
mobile phase
Mobile phase in
gradient mode cannot
be run
Virtually a universal
detector but has limited
sensitivity
Conductivity Charged or polar
compounds
Mobile phase
must be conducting
Very selective and
sensitive
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1.9.8 Normal Phase Liquid chromatography
Normal-phase liquid-liquid chromatography uses a polar stationary phase and less polar
mobile phase. To select an optimum mobile phase, it is best to start with a pure hydrocarbon
mobile phase such as heptanes. If the sample is strongly retained, the polarity of the mobile
phase should be increased, perhaps by adding small amounts of methanol or dioxane. In the
normal phase mode, separation of oil-soluble vitamins, essential oils, nitrophenols, or more
polar homologous series have been performed using alcohol/heptanes as the mobile phase.
1.9.9 Reverse Phase Liquid chromatography
Reverse phase chromatography uses hydrophobic bonded packing, usually with an octadecyl
or octyl functional group and a polar mobile phase, often a partially or fully aqueous mobile
phase. Polar substances prefer the mobile phase and elute first. As the hydrophobic character
of the solutes increases, retention increases. Generally, the lower the polarity of the mobile
phase, the higher is its eluent strength. The elution order of the classes of compounds in table
is reversed (thus the name reverse-phase chromatography). Hydrocarbons are retained more
strongly than alcohols. Also, the eluent strength of the various solvents in reverse-phase
chromatography follows approximately the reverse order given in table. Thus water is the
weakest eluent. Methanol and acetonitrile are popular solvents because they have low
viscosity and are readily available with excellent purity.
Electrochemical Readily oxidizable
or reducible
compounds,
especially
biological samples
Mobile phase
must be conducting
Very selective and
sensitive
Evaporative
Light Scattering
Virtually all
compounds
Fully gradient
compatible, no
limitation on solvent
choice
A universal detector
which is highly sensitive
but not selective.
Mass
Spectrometer
Broad range of
compounds
Must be volatile
solvents & volatile
buffers
Highly sensitive and is
powerful 2nd
dimensional analytical
tool.
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1.9.10 Liquid chromatograph
It is the way of interfacing the 
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1.9.12 Instrumentation
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1.9.13 Sample inlet system
There are two opinions of a sample inlet system
 The sample introduced as neutral species through a controlled vacuum leak
followed by ionization in vacuum chamber.
 Create the ion at atmospheric pressure and then introduced the ion in to the mass
spectrometer through a controlled vacuum leak with aid of electrostatic this
process is called API (atmospheric pressure ionization) provide best way when a
dynamic coupling of liquid chromatograph done.
1.9.14 Ionization source
Ionization proceeds by two fundamental processes:
 Loss/gain of an electron
 Loss/gain of a charge particle
An odd electron ions is generated by the gain/loss of an electron. In vacuum generating
method ionic species of identical nominal molecular weight differ only by the mass of an
electron to the neutral specie from which it was generated.
An even electron is produced by gain or loss of even electron specie from a molecule.
There are four common modes of ionization
 Electron ionization (EI)
 Chemical ionization (CI)
 Matrix-Assisted Laser desorption Ionization (MALDI)
 Atmospheric pressure ionization (API)
In LC/MS interfacing Atmospheric Pressure Ionization (API) is the potential Ionization
techniques because
 It gives softer ionization
 It provide convenient interface with liquid chromatograph
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1.9.15 Type of API Source
 Atmospheric Pressure Electro Spray Ionization
 Atmospheric Pressure Chemical Ionization
1.9.16 Atmospheric Pressure Electro Spray Ionization
It is an atmospheric ionization technique in which ions are generated in the solution phase by
evaporation of carrier solvent and ions are produced in gas phase. An appropriate solvent
from LC (liquid chromatographic) system is passed through a metal capillary to which a
static DC voltage is applied to create ionization of effluents. When the solvent got evaporate
the charge density increases creating columbic repulsion and subsequent dissociation of
droplet. Further evaporation of droplet creates an environment in which charge transfer takes
place from the solvent to the analyte. Typically a voltage of 2.5 to 5 kV will be applied to
generate an even electron ion in gas phase. This method is commonly used for high molecular
compounds. Low ionization is observed in this technique due to solvent clustering and
analyte adduct formation, so this is most applicable for LC/MS system.
1.9.17 Atmospheric Pressure Chemical Ionization
It is an ionization technique in which the ionization occurs not in vacuum but at atmospheric
pressure. It is gas phase ionization process whereby gas phase molecules are isolated from the
carrier solvent before ionization. Generally less polar compounds are ionized by this method.
1.10 Glossary
Accuracy: The degree of closeness of the determined value to the nominal or known true
value under prescribed conditions. This is sometimes termed trueness.
Analyte: A specific chemical moiety being measured, which can be intact drug, biomolecule
or its derivative, metabolite, and/or degradation product in a biologic matrix.
Analytical run (or batch): A complete set of analytical and study samples with appropriate
number of standards and QCs for their validation. Several runs (or batches) may be
completed in one day, or one run (or batch) may take several days to complete.
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Biological matrix: A discrete material of biological origin that can be sampled and processed
in a reproducible manner. Examples are blood, serum, plasma, urine, feces, saliva, sputum,
and various discrete tissues.
Calibration standard: A biological matrix to which a known amount of analyte has been
added or spiked. Calibration standards are used to construct calibration curves from which the
concentrations of analytes in QCs and in unknown study samples are determined.
Internal standard: Test compound(s) (e.g. structurally similar analog, stable labeled
compound) added to both calibration standards and samples at known and constant
concentration to facilitate quantification of the target analyte(s).
Limit of detection (LOD): The lowest concentration of an analyte that the bioanalytical
procedure can reliably differentiate from background noise.
Lower limit of quantification (LLOQ): The lowest amount of an analyte in a sample that
can be quantitatively determined with suitable precision and accuracy.
Matrix effect: The direct or indirect alteration or interference in response due to the presence
of unintended analytes (for analysis) or other interfering substances in the sample.
Method: A comprehensive description of all procedures used in sample analysis.
Precision: The closeness of agreement (degree of scatter) between a series of measurements
obtained from multiple sampling of the same homogenous sample under the prescribed
conditions.
Quantification range: The range of concentration, including ULOQ and LLOQ, that can be
reliably and reproducibly quantified with accuracy and precision through the use of a
concentration-response relationship.
Recovery: The extraction efficiency of an analytical process, reported as a percentage of the
known amount of an analyte carried through the sample extraction and processing steps of the
method.
Reproducibility: The precision between two laboratories. It also represents precision of the
method under the same operating conditions over a short period of time.
Sample: A generic term encompassing controls, blanks, unknowns, and processed samples,
as described below:
Blank: A sample of a biological matrix to which no analytes have been added that is used to
assess the specificity of the bioanalytical method.
Quality control sample (QC): A spiked sample used to monitor the performance of a
bioanalytical method and to assess the integrity and validity of the results of the unknown
samples analyzed in an individual batch.
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Unknown: A biological sample that is the subject of the analysis.
Selectivity: The ability of the bioanalytical method to measure and differentiate the analytes
in the presence of components that may be expected to be present. These could include
metabolites, impurities, degradants, or matrix components.
Stability: The chemical stability of an analyte in a given matrix under specific conditions for
given time intervals.
Standard curve: The relationship between the experimental response value and the
analytical concentration (also called a calibration curve).
System suitability: Determination of instrument performance (e.g., sensitivity and
chromatographic retention) by analysis of a reference standard prior to running the analytical
batch.
Upper limit of quantification (ULOQ): The highest amount of an analyte in a sample that
can be quantitatively determined with precision and accuracy.
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3. REVIEW OF LITERATURE
I. Salem, Musab Alkhatib, Naji Najib et al done LC-MS/MS determination of betamethasone
and its phosphate and acetate esters in human plasma after sample stabilization.
Liljana Bogdanovska, Mirjana Popovska, Aneta Dimitrovska et al Studied the development
and validation of RP-HPLC method for determination of betamethasone dipropionate in gingival
crevicular fluid.
Song Ja-park, Yun-je Kim et al done the Analysis of corticosteroids in urine by HPLC and
thermospray LC-MS method.
Mahesh N. Samtani, Willam J et al studied for quantification of dexamethasone and
corticosterone in rat biofluids and fetal tissue using highly sensitive LC/MS/MS method.
Valerie A. Frerichs, Kathleen. M. Tornatore et al performed determination of the
glucocorticoids such as prednisone,prednisolone,dexamethasone and cortisol in human serum
using liquid chromatography coupled to tandem mass spectrometry.
Kumar V., Mostafa S., Kayo M., et al done HPLC determination of dexamethasone in human
plasma and its applications to an in vitro release study from endovascular stents.
N. Goyal, E. Goldberg et al done the determination of dexamethasone, dexamethasone 21-
acetate and paclitaxel in a simulated biological matrix by RP-HPLC method.
Isam I. Salem, Musab Alkhatib, Naji Najib et al done the LC–MS/MS determination of
betamethasone and its phosphate and acetate esters in human plasma after sample stabilization.
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S.A. Doppenschmitt, B. Scheidel, J.P. Surmann et al Performed simultaneous determination of
prednisolone, prednisolone acetate and hydrocortisone in human serum by high performance
liquid chromatography.
Majid, Oneeb, Akhlaghi, Fatemeh et al performed simultaneous determination of plasma
prednisolone, prednisone and cortisol levels by high performance liquid chromatography.
Robert L Taylor, Dwaine Machacek et al validation of high throughput liquid
chromatography-mass spectrometry method for  prednisolone.
Syed Naeem Razzaq, Islam Ullah Khan et al done the  Stability indicating HPLC method for
the simultaneous determination of moxifloxacin and prednisolone in pharmaceutical
formulations.
Raval Kashyap, E.V.S. Subrahmanyam et al done the Development and validation of UV
spectroscopy method for the estimation of prednisolone in bulk and dosage form.
Mohammed Shahid Ali, Mohsin Ghori et al done the Simultaneous Determination of
Ofloxacin, Tetrahydrozoline Hydrochloride, and Prednisolone Acetate by High-Performance
Liquid Chromatography.
Ahi Shobha, Dubey Sachin et al done the Identification of Prednisolone, Methylprednisolone
and Their Metabolites in Human urine using HPLC (+) ESI-MS/MS and Detection of Possible
Adulteration in Indian Herbal Drug Preparations.
Robert L. Taylor, Stefan K. Grebe, Ravinder J. Singh et al done the Quantitative, highly
sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic
corticosteroids.
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S.No. Parameter
1 Structure of Betametha
2 Drug category
3 Chemical formula
4 Molecular weight
5 IUPAC Name
6 Bioavilability
7 Half Life
8 Metabolism
9 Routes
10 Excretion
4. DRUG PROFILE
Betamethasone
Description
sone
Corticosteroid
C22H29FO5
392.461
(8S,9R,10S,11S,13S,14S,16S,17R)-9-fl
dihydroxy-17-(2-hydroxyacetyl)-10,13,16
6,7,8,9,10,11,12,13,14,15,16,17-dodec
cyclopenta[a]phenanthren-3-one
-
36-54 hours
hepatic CYP3A4
Oral,Topical,IM
Renal (in urine)
uoro- 11,17-
-trimethyl-
ahydro- 3H-
Drug Profile
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S.No. Parameter
1 Structure of Dexametha
2 Drug category
3 Chemical formula
4 Molecular weight
5 IUPAC Name
6 Bioavilability
7 Half Life
8 Metabolism
9 Routes
10 Excretion
Dexamethasone
Description
sone
Corticosteroid
C22H29FO5
392.461 g/mol
(8S,9R,10S,11S,13S,14S,16R,17R)-9- F
dihydroxy-17-(2-hydroxyacetyl)-10,13,16
6,7,8,9,10,11,12,13,14,15,16,17- dodec
cyclopenta[a]phenanthren-3-one
80-90%
190 mins
Hepatic
Oral, IV, IM, SC and IO
Urine (65%)
luoro-11,17-
-trimethyl-
ahydro-3H-
Drug Profile
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 39
S.No. Parameter
1 Structure of Prednisolone
2 Drug category
3 Chemical formula
4 Molecular weight
5 IUPAC Name
6 Bioavilability
7 Half Life
8 Metabolism
9 Routes
10 Excretion
Prednisolone
Description
Corticosteroid
C21H28O5
360.444 g/mol
(11β)-11,17,21-trihydroxypregna-1,4-di
-
2-3 hours
Hepatic
Oral, Nasal, Rectal, IV, Injection
Urine
ene-3,20-dione
Materials and Methods
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5. MATERIALS AND METHODS
5.1 List of materials used
1) API of Betamethasone, Dexamethasone & Prednisolone respectively.
2) Rat plasma
3) Solvents used for extraction process:
 Water for HPLC grade (Millie Q or equivalet)
 Ethyl  acetate (HPLC grade)
 Diethyl ether
 Chloroform
 Dichloromethane
5.2 Steps followed in developmental study
 Study of literature review
 Proposed protocols or parameters for extraction process & validation were established
 Find out the probable correct Cmax for our drug.
 Calculations to decide LLOQ, ULOQ/HQC, MQC.
 Selection of internal standard
 Procurement of plasma sample
 Method optimization of sample with different solvent to get maximum %recovery
- Approximately analysis with 5 diff. solvents.
 Individual reading for Blank plasma.
 Individual reading for internal std.
 Individual runs of LQC, MQC, HQC, LLOQ, ULOQ.
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 Readings for calibration curve
- Singlet or doublet could be taken for each concentration.
 Validation
- For Accuracy: 5 replicates of LQC, MQC and HQC for 5 days.
- Selectivity: 6 plasma obtained from 6 different sources.
 Stability Studies
- Freeze-thaw method: LQC and HQC, 5 samples of each were freeze-thaw for 3
cycles of 12, 24 and 48hrs.
- Bench-top: Short term analysis between 2-24hrs.
- Long term analysis
- Plane stock solution stability.
 Experimental studies were conducted
 Analytical results were evaluated
 Statistical evaluation was carried out
 Report was prepared documenting all the results
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Fig. 5.1 Instrument information
System: HPLC Binary Gradient System
Model no.: HPLC 3000 Series
Company: Analytical Technologies Ltd.
Detector: UV-3000-M
Pump: P-3000-M Reciprocating (40MPa)
Column: Grace C18 (250mm x 4.6ID, Particle size: 5 micron)
Software: HPLC Workstation
Balance: Wenser High Precision Balance
Model: PGB 100
Max: 100gm Min: 0.001gm
Sonicator: Wenser Ultra Sonicator
Model: WUC- 4L
Capacity: 4 Liter
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5.3 Methods used & optimization parameters
Name of Drug-Betamethasone
 Development of chromatographic condition
The chromatogram was developed initially using separation condition such as mobile
phase (methanol:water in the ratio of 10:90 in increasing order). The system was used
Analytical technologies Lts. Model no. 3000Series as mentioned above. The optimized
chromatographic conditions were optimized using a mobile phase methanol:water in the
ratio of 60:40 at flow rate 0.9ml/min for betamethasone with the stationary phase was
used as Grace C18column(250mm x 4.6ID,partical size:5 micron).
 Standard solution preparation
Standard solutions were prepared by using HPLC grade methanol and water in the ratio
1:1. Initially 10 mg of Betamethasone was weighted and transferred into the standard
flask.In that combined solvent (methanol and water) added and finally made the volume
with the same up to 100ml to get 100ppm stock solution. The stock solution further
serialy diluted and was used for the analysis. The stock solution was maintained
refrigerated at 8ºC.
 Extraction method
In this process first take 1 ml of plasma from sample which is previously stored at 5-70C.
In this add 0.0125 milliliter of 1ppm of drug(Betamethasone) which is prepared in
methanol:water combination & 0.125 milliliter of 1ppm of internal standard. After this
vortex the above prepared mixture for 3 mins. Also in this add 0.200 milliliter of 1% of
hydrochloric acid to provide acidic nature to the plasma. Again vortex the above mixture
for 3-5 mins. In this add ethyl acetate which act as a extracting solvent & again vortex the
mixture for 3-5 mins. Now withdraw 2ml of ethyl acetate in which drug is extracted in
fresh tube & finally allow to evaporate the solvent which will leave dried drug in tube &
dilute it with 0.500 milliliter of mobile phase.
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Table no 5.1 Summary for Older methods
Name of Authors
(Literature review)
Analytical
method
Mobile phase Column used Flow rate
Liming peng,tivader
farcas etl
HP 1100 LC Formic
acid:water
Gemini 5µm,C18
150X3.0 mm
0.6ml/min
Isam salem,musab
alkhatib etl
LC-MS/MS - C8 column -
Robert taylor,Stefan
geebe etl
LC-MS/MS Reversed phase
column
Table no 5.2 Summary for Optimized method
Column used Mobile phase Flow rate Wavelength Observation Result
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(10:90)
0.9ml/min 242nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(20:80)
0.9ml/min 242nm Very low
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(40:60)
0.9ml/min 242nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(80:20)
0.9ml/min 242nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
Methanol:water
(50:50)
0.9ml/min 242nm Improved
resolution
Method
rejected
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size: 5 micron)
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(60:40)
0.9ml/min 242nm Good
resolution
Method
accepted
Table no 5.3 Different ranges of concentrations for preparation of standards for
Betamethasone
S.No Sample Concentration of Drug
(ng/ml)
Concentration of Internal
standard (ng/ml)
1 Std-A 10 80
2 Std-B 10 80
3 Std-C 20 80
4 Std-D 60 80
5 Std-E 120 80
6 Std-F 160 80
Name of Drug-Dexamethasone
 Development of chromatographic condition
The chromatogram was developed initially using separation condition such as mobile
phase (methanol:water in the ratio of 10:90 in increasing order). The system was used
Anaytical technologies Lts. Model no. 3000Series as mentioned above. The optimized
chromatographic conditions were optimized using a mobile phase methanol:water in the
ratio of 40:60 at flow rate 1.0ml/min for dexamethasone with the stationary phase used as
Grace C18column(250mm x 4.6ID,partical size:5 micron)
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 Standard solution preparation
Standard solutions were prepared by using HPLC grade methanol and water in the ratio
1:1. Initially 10 mg of drug was weighted and transferred into the standard flask.In that
combined solvent (methanol and water) added and finally made the volume with the
same up to 100ml to get 100ppm stock solution. The stock solution further serialy diluted
and was used for the analysis. The stock solution was maintained refrigerated at 8ºC.
 Extraction method
In this process first take 1 ml of plasma from sample which is previously stored at 5-70C.
In this add 0.0125 mililitre of 1ppm of drug (Dexamethasone) which is prepared in
methanol:water combination & 0.125 mililiter of 1ppm of internal standard. After this
vortex the above prepared mixture for 3 mins. Also in this add 0.200 mililiter of 1% of
hydrochloric acid to provide acidic nature to the plasma.Again vortex the above mixture
for 3-5 mins. In this add ethyl acetate which act as a extracting solvent & again vortex the
mixture for 3-5 mins. Now withdraw 2ml of ethyl acetate in which drug is extracted in
fresh tube & finaly allow to evaporate the solvent which will leave dried drug in tube &
dilute it with 0.500 mililiter of mobile phase.
Table no 5.4 Older methods
Name of Authors
(Literature review)
Analytical
method
Mobile phase Column used Flow rate
Kumar V,Mosta S, etl HPLC Acetonitrile:
triple distilled
water (28:72)
C18 column 1.2 ml/min
Goyal N, El Achchabi
etl
LC-
MS/MS
Acetonitrile:
phosphoric acid:
water
C18 column -
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Table no 5.5 Summary for Optimized method
Column used Mobile phase Flow rate Wavelength Observation Result
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(10:90)
1.0
ml/min
240nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(20:80)
1.0
ml/min
240nm Very low
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(30:70)
1.0
ml/min
240nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(80:20)
1.0
ml/min
240nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(50:50)
1.0
ml/min
240nm Improved
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(40:60)
1.0
ml/min
240nm Good
resolution
Method
accepted
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Table no 5.6 Different ranges of concentrations for preparation of standards for
Dexamethasone
S. No Sample Concentration of Drug
(ng/ml)
Concentration of Internal
standard (ng/ml)
1 Std-A 70 480
2 Std-B 70 480
3 Std-C 140 480
4 Std-D 420 480
5 Std-E 840 480
6 Std-F 1120 480
Name of Drug- Prednisolone
 Development of chromatographic condition
The chromatogram was developed initially using separation condition such as mobile
phase (methanol:water in the ratio of 10:90 in increasing order). The system was used
Analytical technologies Lts. Model no. 3000Series as mentioned above. The optimized
chromatographic conditions were optimized using a mobile phase methanol:water in the
ratio of 70:30 at flow rate 0.9ml/min with the stationary phase used as Grace
C18column(250mm x 4.6ID,partical size:5 micron)
 Standard solution preparation
Standard solutions were prepared by using HPLC grade methanol and water in the ratio
1:1. Initially 10 mg of Prednisolone was weighted and transferred into the standard
flask.In that combined solvent (methanol and water) added and finally made the volume
with the same up to 100ml to get 100ppm stock solution. The stock solution further
serialy diluted and was used for the analysis. The stock solution was maintained
refrigerated at 8ºC.
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 Extraction method
In this process first take 1 ml of plasma from sample which is previously stored at 5-70C.
In this add 0.0125 milliliter of 1ppm of drug (Prednisolone) which is prepared in
methanol:water combination & 0.125 milliliter of 1ppm of internal standard. After this
vortex the above prepared mixture for 3 mins. Also in this add 0.200 milliliter of 1% of
hydrochloric acid to provide acidic nature to the plasma. Again vortex the above mixture
for 3-5 mins. In this add ethyl acetate which act as a extracting solvent & again vortex the
mixture for 3-5 mins. Now withdraw 2ml of ethyl acetate in which drug is extracted in
fresh tube & finally allow to evaporate the solvent which will leave dried drug in tube &
dilute it with 0.500 milliliter of mobile phase.
Table no 5.7 Older methods
Name of Authors
(Literature review)
Analytical
method
Mobile phase Column used Flow rate
Ahi Shobha,Dubey
sachin, etl
LC-MS/MS Formic acid:Acetonitrile
(50:50)
C-18,ODS-3
(3µm,50mm×
4.6mm)
0.6ml/min
Liming
peng,Tivadar farcas,
etl
HP 1100 LC
system
Formic acid:Water Gemini
5µm,C18
150X3.0 mm
0.6ml/min
Majid O,Alhlaghi F,
etl
HPLC Isopropanol:Water Supelcosil
LC-18-
DB(5µm,150
mm× 4.6mm)
1.2ml/min
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Table no 5.8 Summary for Optimized method
Column used Mobile phase Flow rate Wavelength Observation Result
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(10:90)
0.9ml/min 238nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(20:80)
0.9ml/min 238nm Very low
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(40:60)
0.9ml/min 238nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(50:50)
0.9ml/min 238nm Poor
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(60:40)
0.9ml/min 238nm Improved
resolution
Method
rejected
Grace C18
(250mm x
4.6ID, Particle
size: 5 micron)
Methanol:water
(70:30)
0.9ml/min 238nm Good
resolution
Method
accepted
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Table no 5.9 Different concentration ranges for preparation of standards for
Prednisolone
S. No Sample Concentration of Drug
(ng/ml)
Concentration of Internal
standard (ng/ml)
1 Std-A 100 80
2 Std-B 100 80
3 Std-C 200 80
4 Std-D 600 80
5 Std-E 1200 80
6 Std-F 1600 80
 Statistical calculations
Following formulas were used for different statistical calculations in the proposed work.
1) Coefficient of variation:
CV = (SD/ Mean) x 100
Where,
CV= Coefficient of variation
SD = Standard deviation
2) Standard deviation:
S2 = Σ(X-M)2 /n-1
Where,
Σ = Sum of
X = Sample value
M = Mean value of samples
N = Sample size (number of samples)
3) Relative Standard deviation:
RSD = S2 / X1*100
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4) Resolution:
R=2(t2 –t1) / (W2+W1)
Where,
R = Resolution between a peak of interest (peak 2) and peak preceding it (peak 1)
W2 = width of the base of component peak 2
W1 = width of the base of component peak 2
t2 = retension time of the second peak measured from point of injection
t1 = retension time of the second peak measured from point of injection
5) Peak asymmetry:
T=W0.05 / 2f
Where,
T = Peak asymmetry or tailing factor W0.05 = Distance from the leading edge to the
tailing edge of the peak, measured at a point 5% of the peak height from the baseline.
f= distance from the peak maximum to the leading edge of the peak.
6) Theoretical plate per meter:
n = (5.54 Vr2) / Wh2
Where,
n = Number of theoretical plates per meter.
Vr = the distance along the base line between the point of injection and a perpendicular
dropped from the maximum of the peak of interest.
Wh = the width of the peak of interest at half peak height.
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6. RESULTS AND ANALYSIS
Name of Drug: Betamethasone
Trial graphs for Betamethasone
Sample name: Blank
Run time: 6.86min
Sample name: Blank+IS
Run time: 12.49min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.383 7919 0.00 13023 0.99
Sample name: LQC Trial
Run time: 7.59 min
Sample name: Betamethasone extraction trial
Run time: 9.55min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.302 52372 0.00 14303 2.44
Selectivity
The desired method used RP-HPLC method for separation of betamethasone from paracetamol
(IS) as well as plasma sample and was shown to be selective for the analyte and its IS (retention
times for betamethasone and paracetamol were 5.80 and 7.20 minutes respectively).No
interfering peaks were observed with the same retention time of the analyte when different
plasma samples were analysed. The chromatograms of blank plasma and plasma sample spiked
with drugs respectively are given below.
Chromatographic conditions
Sample Name: Blank + Paracetamol as an internal standard
Wavelength: 242nm
Mobile Phase: Methanol:Water (60:40)
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Sample volume: 100µlFlow rate: 0.9 ml/min
Pressure: 10-11MPa
Run time: 12.80min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.356 34003 0.00 12491 1.06
FOR BLANK PLASMA SAMPLE
Chromatographic conditions
Sample Name: Blank Plasma Sample
Wavelength: 242nm
Mobile Phase: Methanol:Water (60:40)
Sample volume: 100µl
Flow rate: 0.9 ml/min
Pressure: 10-11MPa
Run time: 9.97min
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Linearity
Linearity was demonstrated by taking sample concentration ranges from 10.0-160 ng/ml. Fig.
given below shows calibration curve of betamethasone. The calibration curve includes 6
calibration standards which are distributed 0.998 with goodness of fit.
Sample Name: Betamethasone  Std A
Run time: 11.34min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.822 52172 4.05 7363 1.35
7.232 11678 0.00 32496 1.27
Sample Name: Betamethasone Std B
Run time: 11.74min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.818 57698 4.12 5463 1.33
7.238 12670 0.00 7443 1.32
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Sample Name: Betamethasone  Std C
Run time: 11.44min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.758 52910 2.02 3229 1.36
7.113 24459 0.00 3842 1.35
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Sample Name: Betamethasone Std D
Run time: 10.05min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.616 50116 3.67 3507 1.40
6.885 65371 0.00 3087 1.37
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Sample Name: Betamethasone Std E
Run time: 10.24min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.535 58350 5.26 10336 1.41
6.795 85899 0.00 11483 1.37
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Sample Name: Betamethasone Std F
Run time: 10.14min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.049 54399 5.11 4468 1.32
7.375 129176 0.00 5148 1.27
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Table no. 6.1: Observation table for linearity graph
Sample Name Concentration ratio of
sample and internal
standard
Area ratio of sample and
internal standard
Std-A 0.125 0.225
Std-B 0.125 0.225
Std-C 0.25 0.383
Std-D 0.75 0.983
Std-E 1.5 1.752
Std-F 2.0 2.425
Fig No.6.1: Linearity graph
(Limit: The R² value should be near to 1)
y = 1.089x + 0.100
R² = 0.998
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FOR LLOQ
Chromatographic conditions
Sample Name: Betamethasone 5ng/ml + Paracetamol 80ng/ml
Wavelength: 242nm
Mobile Phase: Methanol:Water (60:40)
Sample volume: 100µl
Flow rate: 0.9 ml/min
Pressure: 10-11MPa
Run time: 12.11min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.806 59299 5.06 12643 1.35
7.208 7321 0.00 12680 1.32
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ACCURACY AND PRECISION
Accuracy and Precision was evaluated by analyzing 5 bathches. Each batch consist of five
replicates of LQC, MQC and HQC.
Sample Name: Betamethasone HQC 01
Run time: 10.12min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.972 58181 2.40 4101 1.30
7.289 163368 0.00 7378 1.26
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Sample Name: Betamethasone HQC 02
Run time: 10.05 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.093 58302 3.04 5129 1.30
7.438 148297 0.00 4884 1.27
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Sample Name: Betamethasone HQC 03
Run time: 10.05min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.868 59297 3.65 4982 1.33
7.146 162071 0.00 6824 1.29
Sample Name: Betamethasone HQC 04
Run time: 10.06 min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.820 60388 3.50 4422 1.31
7.099 144867 0.00 7398 1.26
Sample Name: Betamethasone HQC 05
Run time: 10.05min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.992 53038 3.40 7210 1.34
7.338 157923 0.00 6123 1.28
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Sample Name: Betamethasone MQC 01
Run time: 10.32min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.623 51057 2.60 5492 1.39
6.904 82197 0.00 7400 1.36
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Sample Name: Betamethasone MQC 02
Run time: 10.94min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.598 50713 2.57 6509 1.40
6.867 84128 0.00 8095 1.37
Sample Name: Betamethasone MQC 03
Run time: 10.34min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.601 53708 3.40 5955 1.41
6.873 82287 0.00 6114 1.38
Sample Name: Betamethasone MQC 04
Run time: 11.60min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.612 56502 4.30 9594 1.34
6.911 80273 0.00 5267 1.44
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Sample Name: Betamethasone MQC 05
Run time: 10.66min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.795 58389 2.96 7546 1.36
7.240 87071 0.00 6090 1.35
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Sample Name: Betamethasone LQC 01
Run time: 9.61min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.787 53775 2.87 6785 1.36
7.182 16708 0.00 8460 1.33
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Sample Name: Betamethasone LQC 02
Run time: 11.45min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.780 55937 2.98 6459 1.33
7.168 15903 0.00 9706 1.29
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Sample Name: Betamethasone LQC 03
Run time: 10.11min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.770 48969 4.12 8354 1.34
7.161 18158 0.00 5001 1.33
Sample Name: Betamethasone LQC 04
Run time: 10.78min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.787 53350 3.60 7942 1.32
7.169 51329 0.00 6531 1.21
Sample Name: Betamethasone LQC 05
Run time: 10.32min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.785 51072 4.12 7569 1.34
7.173 16098 0.00 7739 1.33
The precision and accuracy of the method for each concentration levels are represented in
following Table.
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Table No.6.2 Observation table for Accuracy & Precision
Standard Deviation Accuracy Precision
Conc.
Conc.
Ratio
Area
Ratio
Mean SD %SD %RSD
LQC
0.1875 0.3107
0.322708 0.031953 9.9014 9.9014
0.1875 0.2843
0.1875 0.3708
0.1857 0.3325
0.1857 0.3152
MQC
1.5 1.6099
1.54257 0.094421 6.1214 6.1214
1.5 1.6589
1.5 1.5321
1.5 1.4207
1.5 1.4912
HQC
2.5 2.8079
2.69222 0.226147 8.4 8.42.5 2.5436
2.5 2.7332
2.5 2.3989
2.5 2.9775
(Standard Limit-%SD & % RSD should be less than 15%)
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Table No.6.3 Observation table for Coefficient Variance (CV)
Sr.No Concentration Concentration ratio Coefficient Varience
1 LQC 0.1875 0.178753
2 MQC 1.5 0.307289
3 HQC 2.5 0.475549
Fig No. 6.2: Coefficient Variance graph
RECOVERY
The recovery was evaluated by comparing response of extracted and unextracted samples.The
average recovery for Betamethasone in plasma was found to around 73.2%.
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UNEXTRACTED SAMPLE
Sample Name: Betamethasone LQC
Run time: 9.88min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.764 70467 2.76 6490 1.22
6.981 24325 0.00 7223 1.21
5.7
64'
6.9
81'
0
2
4
6
8
10
1 2 3 4 5 6 7 8 9 10
Results and Analysis
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 80
Extracted sample
Sample Name: Betamethasone LQC
Run time: 11.37min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.827 58241 3.60 7205 1.35
7.259 15576 0.00 8698 1.33
For stability study
Stability studies were performed to evaluate the stability of Betamethasone both in aqueous
solution and in plasma after exposing to various stress conditions. The stability studies
performed include bench top stability, freeze thaw stability, long term and short term stock
stability. Betamethasone was found to be stable for three freeze and thaw cycles.
1. Bench top Stability:
A. Short Term Analysis: 2, 12 and 24hrs.
B. Long Tem Analysis: 10, 20 and 30days
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Sample Name: Betamethasone HQC 2hrs
Run time: 10.62min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.875 52260 3.26 7020 1.21
7.307 160343 0.00 5278 1.17
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Sample Name: Betamethasone HQC 12hrs
Run time: 13.36min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.863 50613 3.39 6790 1.34
7.089 146555 0.00 7999 1.19
Sample Name: Betamethasone HQC 24hrs
Run time: 9.86min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.834 42589 3.42 5465 1.33
7.048 148994 0.00 8866 1.19
Sample Name: Betamethasone HQC 10days
Run time: 10.26min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.642 26804 3.50 7791 1.02
7.163 53669 0.00 4033 1.42
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Sample Name: Betamethasone HQC 20 days
Run time: 12.04min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.669 20940 2.00 4832 1.14
7.210 45603 0.00 6551 1.40
Sample Name: Betamethasone HQC 30days
Run time: 8.88min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.293 7988 1.68 3020 0.92
6.455 1568 0.00 2011 1.05
Sample Name: Betamethasone LQC 2hrs
Run time: 9.33min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.820 52185 3.54 5969 1.22
7.040 16299 0.00 6194 1.19
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Sample Name: Betamethasone LQC 12hrs
Run time: 9.27min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.810 51139 2.74 7610 1.21
7.015 14362 0.00 8333 1.18
Sample Name: Betamethasone LQC 24hrs
Run time: 9.14min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.804 49264 3.12 4279 1.21
7.013 9487 0.00 4590 1.19
Sample Name: Betamethasone LQC 10days
Run time: 10.94min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.361 8235 1.40 3847 1.04
6.983 2981 0.00 2654 1.15
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Sample Name: Betamethasone LQC 20days
Run time: 7.75min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.793 1505 1.49 1387 0.97
6.989 1521 0.00 1590 0.98
Sample Name: Betamethasone LQC 30days
Run time: 9.16min
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Fig No 6.3 Degradation graph for Bench top stabilty
2. Freeze thaw Cycles Stability: Each Cycle at 12, 24 and 48hrs.
Sample Name: Betamethasone HQC 12hrs
Run time: 10.06min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.144 54736 2.89 6806 1.22
7.628 142033 0.00 5973 1.17
Sample Name: Betamethasone HQC 24hrs
Run time: 10.09min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.888 42534 2.60 7167 1.33
7.136 135780 0.00 5270 1.19
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Sample Name: Betamethasone HQC 48hrs
Run time: 10.72min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.166 27886 3.06 6605 1.24
7.648 63152 0.00 5483 1.18
Sample Name: Betamethasone LQC 12hrs
Run time: 9.64min
6
.1
6
6
'
7
.6
4
8
'
0
1
2
3
4
1 2 3 4 5 6 7 8 9 10 11
6.17
8'
7.7
38'
0
2
4
6
8
10
1 2 3 4 5 6 7 8 9 10
Results and Analysis
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 92
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.178 50286 4.32 6005 1.21
7.738 15745 0.00 6312 1.19
Sample Name: Betamethasone LQC 24hrs
Run time: 9.91min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.433 53134 3.04 5618 1.22
8.089 12958 0.00 5116 1.34
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Sample Name: Betamethasone LQC 48hrs
Run time: 9.41min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.196 36084 3.16 8532 1.21
7.763 7002 0.00 7835 1.40
Fig No.6.4: Degradation graph for Freeze thaw stabilty
6.19
6'
7.76
3'
-1
0
1
2
3
4
5
6
7
8
1 2 3 4 5 6 7 8 9
0
100000
200000
300000
400000
500000
24hrs 48hrs 72hrs
Ar
ea
Degradation  Graph
Results and Analysis
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 94
3. Plane Solution Stability: 24, 48 and 72hrs.
Sample Name: Betamethasone HQC 24 hrs
Run time: 9.50min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.883 68704 2.69 5480 1.28
7.143 225871 0.00 5779 1.18
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Sample Name: Betamethasone HQC 48 hrs
Run time: 9.60min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.812 65333 2.25 5484 1.34
7.038 216633 0.00 7595 1.19
Sample Name: Betamethasone HQC 72 hrs
Run time: 9.57min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.848 641017 2.86 6036 1.33
7.086 215088 0.00 8144 1.19
Sample Name: Betamethasone LQC 24hrs
Run time: 9.88min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.764 70467 2.76 6490 1.22
6.981 24325 0.00 7223 1.21
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Sample Name: Betamethasone LQC 48hrs
Run time: 10.38min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.328 62638 3.08 5902 1.21
7.898 21167 0.00 9576 1.26
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Sample Name: Betamethasone LQC 72hrs
Run time: 9.72min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
6.304 58222 2.32 6561 1.21
7.876 19434 0.00 5950 1.42
Fig No.6.5: Degradation graph for plane solution stability
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Name of Drug: Dexamethasone
Trial graphs for Dexamethasone
Sample name: Dexamethasone Plasma Recovery
Run time: 8.64min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.447 378082 0.78 3418 1.21
5.469 609582 0.90 3106 1.27
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Sample Name: Dexamethasone LQC
Run time: 8.59min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.128 49651 2.52 5971 1.16
6.029 202636 0.00 5384 1.16
Selectivity
The desired method used RP-HPLC method for separation of Dexamethasone from Felodipin
(IS) as well as plasma sample and was shown to be selective for the analyte and its IS (retention
times for dexamethasone and felodipin were 5.44 and 6.33 minutes respectively).No interfering
peaks were observed with the same retention time of the analyte, when different plasma samples
were analysed.
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Sample name: Drug+IS (Felodipin)
Run time: 8.92min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.533 27054 3.15 5263 1.10
6.459 44529 0.00 8960 1.13
Linearity
Linearity was demonstrated by taking sample concentration ranges from 70-1120 ng/ml. Fig.
given below showes calibration curve of dexamethasone.The calibration curve includes 6
calibration standards which are distributed 0.998  with goodness of fit.
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Sample Name: Dexamethasone Standard A
Run time: 8.76min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.448 35019 2.66 8380 1.12
6.346 208242 0.00 7625 1.15
Sample Name: Dexamethasone Standard B
Run time: 8.48min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.503 34870 2.50 5937 1.10
6.421 201735 0.00 6559 1.14
Sample Name: Dexamethasone Standard C
Run time: 10.49min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.452 32875 2.87 6644 1.12
6.352 211506 0.00 7301 1.15
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Sample Name: Dexamethasone Standard D
Run time: 9.55min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.343 210670 0.00 16558 1.16
6.253 205759 0.00 55523 1.17
Sample Name: Dexamethasone Standard E
Run time: 10.78min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.229 381615 2.07 5834 1.19
6.150 207289 0.00 7707 1.14
Sample Name: Dexamethasone Standard F
Run time: 9.17min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.303 520809 0.00 7683 1.18
6.200 208384 0.00 5308 1.17
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Table No.6.4 Observation table for Linearity graph
Sample Name Concentration ratio of
sample and internal
standard
Area ratio of sample and
internal standard
Std-A 0.1458 0.1748
Std-B 0.1458 0.1748
Std-C 0.2916 0.3368
Std-D 0.875 1.023
Std-E 1.75 1.8369
Std-F 2.333 2.4992
Fig No.6.6: Linearity graph
(Limit: The R² value should be near to 1)
y = 1.049x + 0.042
R² = 0.998
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Accuracy and Precision
Accuracy and Precision was evaluated by analyzing 5 bathches.Each batch consist of five
replicates of LQC, MQC and HQC.
Sample Name: Dexamethasone LQC 01
Run time: 8.23min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.826 48074 2.23 6648 1.14
5.687 202076 0.00 6490 1.17
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Sample Name: Dexamethasone LQC 02
Run time: 8.36min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.829 50576 3.05 5256 1.07
6.704 182915 0.00 12138 1.14
Sample Name: Dexamethasone LQC 03
Run time: 8.62min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.386 47909 2.13 7498 1.12
6.270 198957 0.00 6222 1.13
Sample Name: Dexamethasone LQC 04
Run time: 8.63min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.273 51829 2.15 6460 1.12
6.137 174802 0.00 7470 1.12
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Sample Name: Dexamethasone LQC 05
Run time: 8.77min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.130 49975 2.65 9208 1.05
6.047 175782 0.00 8501 1.15
Sample Name: Dexamethasone MQC 01
Run time: 9.98min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.435 383080 3.07 7274 1.18
6.398 211576 0.00 6602 1.16
Sample Name: Dexamethasone MQC 02
Run time: 11.90min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.513 381373 3.25 6563 1.18
6.495 203236 0.00 6459 1.16
5.5
13
'
6.4
95
'
-3
0
3
6
9
12
15
18
21
24
27
mV
1 2 3 4 5 6 7 8 9 10 11
Results and Analysis
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 112
Sample Name: Dexamethasone MQC 03
Run time: 9.47min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.201 376290 2.84 5303 1.17
6.108 217244 0.00 5068 1.15
Sample Name: Dexamethasone MQC 04
Run time: 9.06min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.409 380874 2.89 5477 1.16
6.341 215097 0.00 5495 1.15
Sample Name: Dexamethasone MQC 05
Run time: 12.86min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.419 358074 2.63 4838 1.17
6.348 225033 0.00 4408 1.15
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Sample Name: Dexamethasone HQC 01
Run time: 8.28min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.369 709820 3.10 4391 1.20
6.278 223255 0.00 6817 1.18
Sample Name: Dexamethasone HQC 02
Run time: 8.25min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.287 679182 3.43 6961 1.19
6.180 219189 0.00 6551 1.16
Sample Name: Dexamethasone HQC 03
Run time: 9.13min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.049 672768 3.08 6145 1.22
5.928 195959 0.00 5834 1.20
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Sample Name: Dexamethasone HQC 04
Run time: 8.70min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.334 684456 2.16 6092 1.20
6.257 199363 0.00 7343 1.17
Sample Name: Dexamethasone HQC 05
Run time: 8.35min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.354 682247 0.00 4181 1.19
6.283 229134 0.00 7903 1.17
The precision and accuracy of the method for each concentration levels are represented in
following Table.
Table No.6.5 Observation table for Accuracy & Precision
Standard Deviation Accuracy Precision
Conc. Conc. Area Mean SD %SD %RSD
LQC
0.218 0.2379
0.2672 0.02642366 9.889096 9.889096
0.218 0.2765
0.218 0.2408
0.218 0.2965
0.218 0.2843
MQC
1.75 1.8106
1.756224 0.10659097 6.069327 6.069327
1.75 1.8765
1.75 1.7321
1.75 1.7707
1.75 1.5912
HQC 2.916 3.1794 3.18508 0.16943189 5.319549 5.319549
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2.916 3.0986
2.916 3.4332
2.916 3.2367
2.916 2.9775
(Standard Limit: %SD & % RSD should be less than 15%)
Table No.6.6 Observation table for Coefficient varience (CV)
Sr.No Concentration Concentration Ratio Coefficient Varience
1 LQC 0.2187 0.162553
2 MQC 1.75 0.326482
3 HQC 2.916 0.411621
Fig No.6.7: coefficient variance graph
Recovery
The recovery was evaluated by comparing response of extracted and unextracted samples.The
average recovery for Dexamethasone in plasma was found to around 75.2%.
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Unextracted sample
Sample Name: Dexamethasone LQC
Run time: 9.13min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.397 102667 1.85 4909 1.09
6.283 259437 0.00 3105 1.17
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Extracted sample
Sample Name: Dexamethasone LQC
Run time: 8.43min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.432 49441 2.67 24800 1.13
6.424 204813 0.00 20030 1.13
For stability study
Stability studies were performed to evaluate the stability of Dexamethasone both in aqueous
solution and in plasma after exposing to various stress conditions. The stability studies
performed include bench top stability, freeze thaw stability, long term and short term stock
stability. Dexamethasone was found to be stable for three freeze and thaw cycles.
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1. Bench top Stability:
A. Short Term Analysis: 2, 12 and 24hrs.
B. Long Tem Analysis: 10, 20 and 30days
Sample Name: Dexamethasone HQC 2hrs
Run time: 8.55min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.333 194966 0.00 8017 1.25
6.301 20332 0.00 8058 1.23
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Sample Name: Dexamethasone HQC 12hrs
Run time: 8.58 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.343 746005 2.17 3522 1.23
6.305 478837 0.00 2413 1.22
Sample Name: Dexamethasone HQC 24 hrs
Run time: 8.84 min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.223 846232 1.91 2379 1.20
6.078 417558 0.00 2857 1.18
Sample Name: Dexamethasone HQC 10 days
Run time: 12.64 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.179 68669 0.00 17233 0.95
6.021 25125 0.00 20823 0.89
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Sample Name: Dexamethasone HQC 20 days
Run time: 10.95 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.105 73748 0.00 13119 0.87
6.438 4511 0.00 43340 1.30
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Sample Name: Dexamethasone HQC 30 days
Run time: 9.47 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.166 225947 2.26 1437 0.87
6.009 212093 0.00 954 0.78
Sample Name: Dexamethasone LQC 2hrs
Run time: 8.88 min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.249 49355 4.25 15869 1.14
6.114 137475 0.00 13267 1.16
Sample Name: Dexamethasone LQC 12 hrs
Run time: 8.25 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.323 168765 2.68 3197 1.15
6.257 216742 0.00 6498 1.15
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Sample Name: Dexamethasone LQC 24 hrs
Run time: 8.51 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.385 62690 4.10 15094 1.13
6.324 148765 0.00 13725 1.15
Sample Name: Dexamethasone LQC 10 days
Run time: 9.36 min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.338 108073 2.74 3337 0.96
6.272 100842 0.00 6955 1.04
Sample Name: Dexamethasone LQC 20 days
Run time: 8.28 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.411 8348 0.00 10179 1.05
6.377 1508 0.00 36817 0.79
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Sample Name: Dexamethasone LQC 30 days
Run time: 8.93 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.383 15462 0.00 12557 0.89
6.309 3166 0.00 44506 0.82
Fig No.6.8: Degradation graph for Bench top stabilty
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2. Freeze thaw Cycles Stability: Each Cycle at 12, 24 and 48hrs.
Sample Name: Dexamethasone HQC 12hrs
Run time: 10.04min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.061 445723 2.87 8146 1.22
5.880 176126 0.00 7328 1.20
Sample Name: Dexamethasone HQC 24hrs
Run time: 9.13min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.140 415491 2.63 4803 1.17
5.977 129790 0.00 6075 1.15
Sample Name: Dexamethasone HQC 48hrs
Run time: 9.30min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.053 343934 2.05 3955 1.05
5.873 109710 0.00 2547 1.06
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Sample Name: Dexamethasone LQC 12hrs
Run time: 8.47min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.508 46109 2.97 4948 1.05
6.473 201594 0.00 5021 1.09
Sample Name: Dexamethasone LQC 24hrs
Run time: 8.33min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.498 44512 3.50 5540 1.07
6.458 190566 0.00 5747 1.12
Sample Name: Dexamethasone LQC 48hrs
Run time: 8.99min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.431 17237 1.90 6084 1.08
6.328 123268 0.00 3847 1.13
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Fig No.6.9: Degradation graph for freeze thaw stability
3. Plane Solution Stability: 24, 48 and 72hrs.
Sample Name: Dexamethasone LQC Day 1
Run time: 9.42min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.524 155631 2.58 4574 1.14
6.525 290156 0.00 6350 1.11
Sample Name: Dexamethasone LQC Day 2
Run time: 8.66min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.464 133670 2.37 3025 1.12
6.363 276223 0.00 5315 1.14
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Sample Name: Dexamethasone LQC Day 3
Run time: 9.13min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.397 102667 1.85 4909 1.09
6.283 259437 0.00 3105 1.17
Fig No.6.10: Degradation graph for plane solution stability
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Name of Drug: Prednisolone
Trial graphs for Prednisolone
Sample name: Prednisolone+IS Trial
Run time: 7.96min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.792 426124 2.87 5325 1.17
5.726 15389 0.00 6464 1.20
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Sample name: Blank Plasma Trial
Run time: 11.23min
Selectivity
The desired method used RP-HPLC method for separation of Prednisolone from Metformin (IS)
as well as plasma sample and was shown to be selective for the analyte and its IS(retention times
for prednisolone and metformin were 5.24 and 6.11 minutes respectively).No interfering peaks
were observed with the same retention time of the analyte, when different plasma samples were
analysed. The chromatogram of blank plasma with IS is given below.
Chromatographic conditions
Sample Name: Blank Plasma+ Metformin
Wavelength: 238nm
Mobile Phase: Methanol:Water (70:30)
Sample volume: 100µl
Flow rate: 0.9 ml/min
Pressure: 10-11MPa
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Run time: 7.77min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.978 9129 0 13603 1.22
Linearity
Linearity was demonstrated by taking sample concentrations ranges from 100-1600 ng/ml. Fig.
given below shows calibration curve of prednisolone.The calibration curve includes 6 calibration
standards which are distributed 0.999 with goodness of fit.
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Prednisolone Std A
Run time: 8.64min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.019 380427 2.69 5352 1.24
6.392 71931 0.00 36513 1.20
Prednisolone Std B
Run time: 9.27min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.704 377156 4.36 5860 1.23
5.911 72917 0.00 18624 1.19
Prednisolone Std C
Run time: 8.41min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.532 379578 9.36 4343 1.24
5.538 119288 0.00 11392 1.19
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Prednisolone Std D
Run time: 8.40min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.792 385671 10.11 6351 1.25
5.863 363909 0.00 12118 1.21
Prednisolone Std E
Run time: 8.68min
3.79
2'
5.86
3'
-5
0
5
10
15
20
25
30
35
40
mV
1 2 3 4 5 6 7 8
3.7
84
'
5.8
54
'
-9
0
9
18
27
36
45
54
63
72
1 2 3 4 5 6 7 8 9
Results and Analysis
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 143
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.784 378107 9.70 5353 1.25
5.854 724731 0.00 12035 1.21
Prednisolone Std F
Run time: 8.34min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.743 373594 9.86 5943 1.24
5.753 965731 0.00 12329 1.20
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Table No.6.7 Observation table for Linearity graph
Sample Name Concentration ratio of
sample and internal
standard
Area ratio of sample and
internal standard
Std-A 0.125 0.1891
Std-B 0.125 0.1891
Std-C 0.25 0.3379
Std-D 0.75 0.939
Std-E 1.5 1.9581
Std-F 2.0 2.5849
Fig No.6.11: Linearity graph
(Limit: The R² value should be near to 1)
y = 1.286x + 0.011
R² = 0.999
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LLOQ (Lower limit of quantification)
Chromatographic conditions
Sample Name: Prednisolone 50ng/ml + Metformin 800ng/ml
Wavelength: 238nm
Mobile Phase: Methanol:Water (70:30)
Sample volume: 100µl
Flow rate: 0.9 ml/min
Pressure: 10-11MPa
Run time: 8.63min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
5.249 409355 4.25 15869 1.14
6.114 193475 0.00 13267 1.16
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Accuracy and Precision
Accuracy and Precision was evaluated by analyzing 5 batches, each batch consist of five
replicates of LQC, MQC and HQC.
Sample name: Prednisolone LQC 01
Run time: 8.79min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.913 348898 9.87 5550 1.23
6.096 110496 0.00 11707 1.20
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Sample name: Prednisolone LQC 02
Run time: 8.30min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.918 385116 6.62 6121 1.25
5.848 109219 0.00 9990 1.20
Sample name: Prednisolone LQC 03
Run time: 8.68min
3.918
'
5.848
'
-4
0
4
8
12
16
20
24
28
32
36
1 2 3 4 5 6 7 8
3.92
8'
6.10
9'
-4
0
4
8
12
16
20
24
28
32
36
1 2 3 4 5 6 7 8
Results and Analysis
Bioanalytical method development and validation of selected corticosteroids in rat plasma using RP-HPLC method 148
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.928 356704 9.65 5948 1.25
6.109 116464 0.00 12145 1.21
Sample name: Prednisolone LQC 04
Run time: 8.21min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.732 342955 9.40 4815 1.24
5.790 125316 0.00 11468 1.20
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Sample name: Prednisolone LQC 05
Run time: 8.11min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.588 332534 9.59 4989 1.23
5.554 113361 0.00 12308 1.20
Sample name: Prednisolone MQC 01
Run time: 8.56min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.784 384887 8.98 3908 1.25
5.864 726783 0.00 12004 1.20
Sample name: Prednisolone MQC 02
Run time: 9.00min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.748 375206 7.79 2683 1.25
5.804 730001 0.00 10158 1.20
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Sample name: Prednisolone MQC 03
Run time: 8.50min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.719 400394 9.70 5266 1.24
5.778 715705 0.00 11779 1.20
Sample name: Prednisolone MQC 04
Run time: 8.33min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.681 395676 9.49 5025 1.23
5.665 720409 0.00 12314 1.20
Sample name: Prednisolone MQC 05
Run time: 11.99min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.911 471747 10.09 6947 1.24
6.045 703480 0.00 11158 1.18
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Sample name: Prednisolone HQC 01
Run time: 8.35min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.624 391930 7.98 3009 1.24
5.568 1208046 0.00 10702 1.20
Sample name: Prednisolone HQC 02
Run time: 8.35min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.769 442159 8.13 3113 1.24
5.793 1213110 0.00 11105 1.19
Sample name: Prednisolone HQC 03
Run time: 8.34min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.743 341324 9.28 4789 1.24
5.795 1218084 0.00 11205 1.19
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Sample name: Prednisolone HQC 04
Run time: 8.40min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.844 432692 7.44 6297 1.25
5.938 1244250 0.00 10328 1.20
Sample name: Prednisolone HQC 05
Run time: 8.22min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.874 407266 4.21 6785 1.16
5.853 1184250 0.00 9464 1.19
The precision and accuracy of the method for each concentration levels are represented in
following Table.
Table No.6.8 Observation Table for Accuracy & Precision
Standard Deviation Accuracy Precision
Conc. Conc. Area Mean SD %SD %RSD
LQC
0.187 0.3167
0.32662 0.0302363 9.257349 9.257349
0.187 0.2836
0.187 0.3265
0.187 0.3654
0.187 0.3409
MQC
1.5 1.8883
1.78666 0.176094 9.85604 9.85604
1.5 1.9456
1.5 1.7875
1.5 1.8207
1.5 1.49122
HQC 2.5 3.0823
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2.5 2.7436
3.0356 0.321548 10.5925 10.59252.5 3.5687
2.5 2.8756
2.5 2.9078
(Standard Limit-%SD & % RSD should be less than 15%)
Table No.6.9 Observation table for Coefficient variance (CV)
Sr.No Concentration Concentration ratio Coefficient Varience
1 LQC 0.1875 0.173886
2 MQC 1.5 0.419635
3 HQC 2.5 0.567052
Fig No.6.12: coefficient variance
Recovery
The recovery was evaluated by comparing response of extracted and unextracted samples.The
average recovery for Prednisolone in plasma was found to around 74.2%.
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Unextracted sample
Sample name: Prednisolone LQC
Run time: 8.43min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.882 454439 8.99 4028 1.24
6.014 178571 0.00 11698 1.20
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Extracted sample
Sample name: Prednisolone LQC
Run time: 8.51min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.926 389472 10.28 6374 1.24
6.099 115389 0.00 12325 1.20
For stability study
Stability studies were performed to evaluate the stability of Prednisolone both in aqueous
solution and in plasma after exposing to various stress conditions. The stability studies
performed include bench top stability, freeze thaw stability, long term and short term stock
stability. Prednisolone was found to be stable for three freeze and thaw cycles.
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1. Bench top Stability:
A. Short Term Analysis: 2, 12 and 24hrs.
B. Long Tem Analysis: 10, 20 and 30days
Sample name: Prednisolone HQC 2hrs
Run time: 8.19min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.624 373538 9.50 5039 1.23
5.594 1189706 0.00 12028 1.17
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Sample name: Prednisolone HQC 12hrs
Run time: 8.38min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.642 326700 8.77 4468 1.36
5.568 1121888 0.00 10765 1.16
Sample name: Prednisolone HQC 24hrs
Run time: 8.51min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.654 298069 9.66 5933 1.22
5.592 1089828 0.00 11870 1.17
Sample name: Prednisolone HQC 10days
Run time: 8.50min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.691 272559 2.91 4252 1.07
5.814 961342 0.00 4366 1.14
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Sample name: Prednisolone HQC 20days
Run time: 10.22 min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.842 74481 2.05 6737 1.11
5.928 121900 0.00 7394 1.11
Sample name: Prednisolone HQC 30days
Run time: 9.49min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.910 7006 2.83 3054 1.11
6.091 11777 0.00 4161 1.12
Sample name: Prednisolone LQC 2hrs
Run time: 8.34min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.876 380350 9.25 6164 1.24
6.019 112361 0.00 10014 1.20
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Sample name: Prednisolone LQC 12hrs
Run time: 8.36min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.875 358827 2.19 5278 1.23
5.920 105470 0.00 4585 1.20
Sample name: Prednisolone LQC 24hrs
Run time: 9.31min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.883 311170 2.37 6785 1.23
6.022 96105 0.00 5515 1.19
Sample name: Prednisolone LQC 10days
Run time: 14.15min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.766 196949 0.00 2601 1.07
5.838 57932 0.00 4718 1.03
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Sample name: Prednisolone LQC 20days
Run time: 8.55min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
4.888 137740 2.01 2337 1.11
5.988 18921 0.00 3344 1.10
Sample name: Prednisolone LQC 30days
Run time: 10.28min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.849 2445 1.80 4977 1.05
4.753 7260 0.00 7859 1.08
Fig No.6.13: Degradation graph for Bench top stability
2. Freeze thaw Cycles Stability: Each Cycle at 12, 24 and 48hrs.
Sample name: Prednisolone HQC 12hrs
Run time: 9.31min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.848 297237 9.43 5700 1.26
5.897 973673 0.00 11081 1.19
Sample name: Prednisolone HQC 24hrs
Run time: 8.20min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.774 200150 10.12 6356 1.24
5.810 779465 0.00 12643 1.19
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Sample name: Prednisolone HQC 48hrs
Run time: 8.13min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.544 157623 9.30 5652 1.27
5.442 680002 0.00 10433 1.21
Sample name: Prednisolone LQC 12hrs
Run time: 8.35min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.860 381671 6.37 3906 1.25
5.981 113762 0.00 6275 1.20
Sample name: Prednisolone LQC 24hrs
Run time: 8.34min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.898 354126 8.69 3490 1.24
6.041 106935 0.00 11885 1.20
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Sample name: Prednisolone LQC 48hrs
Run time: 8.67min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.923 302915 8.68 3458 1.24
6.078 100250 0.00 12034 1.19
Fig No.6.14: Degradation graph for freeze thaw stability
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3. Plane Solution Stability: 24, 48 and 72hrs.
Sample name: Prednisolone HQC Day 1
Run time: 10.24min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.527 455179 2.97 3545 1.25
5.361 1498772 0.00 5883 1.18
Sample name: Prednisolone HQC Day 2
Run time: 12.16min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.768 438181 2.40 5460 1.57
5.714 1475605 0.00 9801 1.15
Sample name: Prednisolone HQC Day3
Run time: 11.55min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.962 377242 5.58 3106 1.60
6.033 1336549 0.00 3902 1.19
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Sample name: Prednisolone LQC Day1
Run time: 8.43min
Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.882 454439 8.99 4028 1.24
6.014 178571 0.00 11698 1.20
Sample name: Prednisolone LQC Day2
Run time: 8.96min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.878 433316 9.11 4134 1.24
6.006 148662 0.00 12041 1.20
Sample name: Prednisolone LQC Day 3
Run time: 8.34min
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Observation Table
Time Area Resolution T.Plate no. Asymmetry
3.885 422145 9.63 5171 1.24
6.019 143373 0.00 11969 1.20
Fig No.6.15: Degradation graph for plane solution stability
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8. SUMMARY AND CONCLUSION
A simple, rapid and sensitive bioanalytical method for quantitative estimation of corticosteroids
such as Betamethasone, Dexamethasone and Prednisolone in rat plasma using RP-HPLC method
has been developed and validated and results obtained are given in the following table.
Table No. 7.1 Summary Table for validation parameters
Sr.No Parameters Acceptance criteria Results obtained
01 Selectivity Should be no interference Pass
02 System suitability Resolution-should be
greater than 1
Theoretical plates-should
be greater than 2000
Tailing/Assymetry factor-
should be less than 2
Pass
03 Accuracy &
Precision
%SD & % RSD should be
less than 15%
pass
04 Linearity R² value should be near to
1
Betamethasone- R² = 0.998
Dexamethasone- R² = 0.998
Prednisolone- R² = 0.999
05 Recovery - Betamethasone- 73.2%
Dexamethasone- 75.2%
Prednisolone- 74.26%
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06 Bench top stability - Short term stock stability-
(2hrs,12hrs,24 hrs)
Long term stock stability-
(10days,20days,30 days)
07 Freeze thaw stability - Pass (3 cycles)
08 Plane solution
stability
- 24hrs,48hrs,72hrs
 By analyzing these above selected drugs (Betamethasone, Dexamethasone and
Prednisolone) and validating with the parameters we conclude that they showed excellent
recovery and reproducibility in all aspects comparing with reported methods. Hence the
developed method will be much useful to analyze plasma samples in rat/human, which
will be more effective when compared with the reported methods.
 The current validated bioanalytical RP-HPLC method for Betamethasone,
Dexamethasone & Prednisolone offers good accuracy and significant advantages in terms
of linearity, stability & selectivity.
 The separation method developed produce acceptable values of recovery. The
chromatogram developed has well resolved peaks of above selected corticosteroids
without any interference.
 By using current developed method we can get maximum absorptivity of selected drugs
as compared to earlier reported methods.
 The developed method is most economical as compared to earlier methods due to use of
Methanol as a solvent.
 In this method I try to maintain minimum retention time (RT) with consideration of
plasma peaks.
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Abstract 
A simple, selective, rapid, precise and economical reverse phase HPLC method has been developed and validated for quantitative 
determination of Betamethasone in plasma. Paracetamol is used as an internal standard. The method was carried out with 
Analytical technologies Lts. Model no. 3000Series. The optimized chromatographic conditions were optimized using a mobile 
phase methanol: water in the ratio of 60:40 at flow rate 0.9ml/min. Stationary phase was used as Grace C18column (250mm x 
4.6ID, partical size: 5 micron). Detection was carried out at 242nm.the method was developed and tested for linearity range of 
10ng/ml to 160ng/ml. The developed method was validated in terms of selectivity, accuracy, precision, linearity and stability 
study. Proposed developed method can be used in bio analytical, bioequivalence & pharmacokinetic studies with desired precision 
and accuracy. 
 
Keywords: HPLC, Vortex mixer, Betamethasone 
Introduction 
Methods of measuring drugs in biological media are 
increasingly important for the study of bioavailability and 
bioequivalence studies, new drug development study, clinical 
pharmacokinetics and therapeutic drug monitoring. Liquid-
liquid extraction is probably the most widely used technique 
because the analyst can remove a drug or metabolite from 
larger concentrations of endogenous materials that might 
interfere with the final analytical determination and also the 
technique is simple, rapid, and has a relatively small cost 
factor per sample. Literature survey revealed that validated 
RP-HPLC method for the quantification of Betamethasone in 
rat plasma is not reported earlier. For estimation of the drugs 
present in biological fluid, HPLC method is considered to be 
more suitable. In this study we have developed compatible 
RP-HPLC method with liquid-liquid extraction process for 
determination of Betamethasone in plasma and the developed 
method is validated as per regulatory requirements.  
 
Materials and Methods 
Chemicals 
API of Betamethasone was gifted by Zydus cadila, 
Ahmadabad. Solvents used are water for HPLC grade (Millie 
Q or equivalet), Ethyl acetate (HPLC grade), Diethyl ether, 
Chloroform and Dichloromethane. 
 
Standard solution preparation  
Standard solutions was prepared by using HPLC grade 
methanol and water in the ratio 1:1. Initially 10 mg of drug 
was weighted and transferred into the standard flask; the 
combined solvent (methanol and water) added and finally 
made the volume with the same up to 100ml to get 100ppm 
stock solution. The stock solution further seriely diluted was 
used for the analysis. The stock solution was maintained 
refrigerated at 8ºC.  
 
Extraction method  
In this process first take 1 ml of plasma from sample which is 
previously stored at 5-70C. In this add 0.0125 mililitre of 
1ppm of drug (Betamethasone) which is prepared in methanol: 
water combination & 0.125 mililiter of 1ppm of internal 
standard. After this vortex the above prepared mixture for 3 
mins. Also in this add 0.200 mililiter of 1% of hydrochloric 
acid to provide acidic nature to the plasma. Again vortex the 
above mixture for 3-5 mins. In this add ethyl acetate which act 
as a extracting solvent & again vortex the mixture for 3-5 
mins. Now withdraw 2ml of ethyl acetate in which drug is 
extracted in fresh tube & finaly allow to evaporate the solvent 
which will leave dried drug in tube & dilute it with 0.500 
mililiter of mobile phase. 
 
Method validation 
The method performance was evaluated for selectivity, 
accuracy, precision, linearity, stability at various conditions 
including bench top stability, freeze thaw stability and 
recovery. 
 
Results and Discussion 
Chromatographic optimization 
The chromatogram was developed initially using separation 
condition such as mobile phase (methanol: water in the ratio 
of 10:90 increasing order). The system was used Anaytical 
technologies Lts. Model no. 3000Series. The optimized 
chromatographic conditions were optimized using a mobile 
phase methanol: water in the ratio of 60:40 at flow rate 
0.9ml/min with the stationary phase was used as Grace 
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C18column (250mm x 4.6ID, partical size: 5 micron). 
The chromatograms of Betamethasone with IS have been 
shown in fig.1.  
 
Selectivity 
The desired method used RP-HPLC method for separation of 
betamethasone from Paracetamol (IS) and was shown to be 
selective for the analyte and its IS (retention times for 
betamethasone and Paracetamol were 5.80 and 7.20 minutes 
respectively). No interfering peaks were observed with the 
same retention time of the analyte when different plasma 
samples were analysed.fig.2 and fig.3 represent the 
chromatograms of blank plasma and plasma sample spiked 
with drugs respectively.  
 
Linearity 
Linearity was demonstrated from 10.0-160 ng/ml.fig.4 shows 
calibration curve of betamethasone. The calibration curve 
includes 6 calibration standards which are distributed 0.758 
with goodness of fit.  
 
Accuracy and Precision 
Accuracy and Precision was evaluated by analyzing 3 
bathches. Each batch consist of three replicates of LQC, MQC 
and HQC. The interday and intraday precision and accuracy of 
the method for each concentration levels are represented in 
Table 1. 
 
Table 1: Intraday and Inter day Precision and Accuracy of Betamethasone. 
 
   
Standard Deviation Accuracy Precision 
Conc. Conc. Area Mean SD %SD %RSD 
LQC 
0.1875 3.0972 
3.0692 0.03857 1.2568 1.2568 0.1875 3.0252 
0.1875 3.0852 
MQC 
1.5 0.0662 
0.066 0.00385 5.8345 5.8345 1.5 0.0621 
1.5 0.0698 
HQC 
2.5 0.0325 
0.036 0.003325 9.2266 9.2266 2.5 0.0365 
2.5 0.0391 
 
 
 
Fig 1: Typical chromatogram of Betamethasone with Paracetamol. 
 
 
 
Fig 2: Typical chromatogram of blank plasma sample. 
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Fig 3: Typical chromatogram of plasma sample spiked with Betamethasone and Paracetamol. 
 
 
 
Fig 4: Calibration curve of Betamethasone. 
 
Recovery 
The recovery was evaluated by comparing response of 
extracted and unextracted samples. The average recovery for 
Betamethasone in plasma was ranged from 85.2 to 88.6% for 
the low, medium and high quality control samples with an 
average of 87.2%. 
 
Stability Studies  
Stability studies were performed to evaluate the stability of 
Betamethasone both in aqueous solution and in plasma after 
exposing to various stress conditions. The stability studies 
performed include bench top stability, freeze thaw stability, 
long term and short term stock stability. Betamethasone was 
found to be stable for three freeze and thaw cycles. 
 
Table 2: Validation Parameters of Betamethasone by HPLC method. 
 
Sr. No Parameters Results 
01 Selectivity Pass 
02 System suitability Pass 
03 Accuracy & precision Pass 
04 Linearity 
Betamethasone- R² = 0.758,  
Dexamethasone- R² = 0.721 
Prdnisolone- R² = 0.725 
05 Recovery Pass 
06 Bench top stability 
 
Short term stock stability-(2hrs, 12hrs, 24 hrs) 
Long term stock stability-(10days, 20days, 30 days) 
07 Freeze thaw stability Pass (3 cycles) 
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Conclusion 
The current validated bio analytical HPLC method for 
Betamethasone offers good accuracy and significant 
advantages in terms of linearity, stability & selectivity. The 
separation method developed produce acceptable values of 
recovery. The chromatograms developed has well resolved 
peaks of above selected corticosteroid without any 
interference. From the results we conclude that the developed 
method can be used in bio analytical, bioequivalence & 
pharmacokinetic studies with desired precision and accuracy. 
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Abstract 
A simple, selective, rapid, precise and economical reverse phase HPLC method has been developed and validated for quantitative 
determination of Prednisolone in plasma. Metformin is used as an internal standard. The method was carried out with Anaytical 
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Keywords: HPLC, vortex mixer, prednisolone 
Introduction 
Methods of measuring drugs in biological media are 
increasingly important for the study of bio availability and 
bioequivalence studies, new drug development study, clinical 
pharmacokinetics and therapeutic drug monitoring. Liquid-
liquid extraction is probably the most widely used technique 
because the analyst can remove a drug or metabolite from 
larger concentrations of endogenous materials that might 
interfere with the final analytical determination and also the 
technique is simple, rapid, and has a relatively small cost 
factor per sample. Literature survey revealed that validated 
RP-HPLC method for the quantification of Prednisolone in rat 
plasma is not reported earlier. For estimation of the drugs 
present in biological fluid, HPLC method is considered to be 
more suitable. In this study we have developed compatible 
RP-HPLC method with liquid-liquid extraction process for 
determination of Prednisolone in plasma and the developed 
method is validated as per regulatory requirements.  
 
Materials and Methods 
Chemicals 
API of Prednisolone was gifted by Zydus cadila, Ahmadabad. 
Solvents used are water for HPLC grade (Millie Q or 
equivalet), Ethyl acetate (HPLC grade), Diethyl ether, 
Chloroform and Dichloromethane. 
 
Standard Solution Preparation  
Standard solutions were prepared by using HPLC grade 
methanol and water in the ratio 1:1. Initially 10 mg of drug 
was weighted and transferred into the standard flask; the 
combined solvent (methanol and water) added and finally 
made the volume with the same up to 100ml to get 100ppm 
stock solution. The stock solution further seriely diluted was 
used for the analysis. The stock solution was maintained 
refrigerated at 8ºC.  
 
Extraction Method  
In this process first take 1 ml of plasma from sample which is 
previously stored at 5-70C. In this add 0.0125 mililitre of 
1ppm of drug (prednisolone) which is prepared in methanol: 
water combination & 0.125 mililiter of 1ppm of internal 
standard. After this vortex the above prepared mixture for 3 
mins. also in this add 0.200 mililiter of 1% of hydrochloric 
acid to provide acidic nature to the plasma. Again vortex the 
above mixture for 3-5 mins. In this add ethyl acetate which act 
as a extracting solvent & again vortex the mixture for 3-5 
mins. Now withdraw 2ml of ethyl acetate in which drug is 
extracted in fresh tube & finaly allow to evaporate the solvent 
which will leave dried drug in tube & dilute it with 0.500 
mililiter of mobile phase. 
 
Method Validation 
The method performance was evaluated for selectivity, 
accuracy, precision, linearity, stability at various conditions 
including bench top stability, freeze thaw stability and 
recovery. 
 
Results and Discussion 
Chromatographic Optimization 
The chromatogram was developed initially using separation 
condition such as mobile phase (methanol: water in the ratio 
of 10:90 increasing order). The system was used Anaytical 
technologies Lts. Model no. 3000Series. The optimized 
chromatographic conditions were optimized using a mobile 
phase methanol: water in the ratio of 70:30 at flow rate 
0.9ml/min respectively with the stationary phase was used as 
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Grace C18 column (250mm x 4.6ID, partical size: 5 micron). 
The chromatograms of Prednisolone with IS have been shown 
in fig.1.  
 
Selectivity 
The desired method used RP-HPLC method for separation of 
Prednisolone from Metformin (IS) and was shown to be 
selective for the analyte and its is (retention times for 
prednisolone and metformin were 5.24 and 6.11 minutes 
respectively).No interfering peaks were observed with the 
same retention time of the analyte when different plasma 
samples were analysed.fig.2 and fig.3 represent the 
chromatograms of blank plasma and plasma sample spiked 
with drugs respectively.  
 
Linearity 
Linearity was demonstrated from 100-1600 ng/ml.fig.4 
showes calibration curve of Prednisolone. The calibration 
curve includes 6 calibration standards which are distributed 
0.999 with goodness of fit.  
 
Accuracy and Precision 
Accuracy and Precision was evaluated by analyzing 5 
bathches, each batch consist of five replicates of LQC, MQC 
and HQC. The precision and accuracy of the method for each 
concentration levels are represented in Table 1. 
 
Table 1: Intraday and Interday Precision and Accuracy of Prdnisolone 
 
   
Standard Deviation Accuracy Precision 
Conc. Conc. Area Mean SD %SD %RSD 
LQC 
0.187 3.164 
3.374 0.162158873 4.80613138 4.80613137 
0.187 3.525 
0.187 3.41 
0.187 3.25 
0.187 3.521 
MQC 
1.5 0.5295 
0.555 0.039515351 7.11296242 7.112962423 
1.5 0.5982 
1.5 0.5025 
1.5 0.5621 
1.5 0.5854 
HQC 
2.5 0.3244 
0.33466 0.011809234 3.52872577 3.528725774 
2.5 0.3521 
2.5 0.3254 
2.5 0.3302 
2.5 0.3412 
 
 
 
Fig 1: Typical chromatogram of Prednisolone with Metformin 
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Fig 2: Typical chromatogram of blank plasma sample 
 
 
 
Fig 3: Typical chromatogram of plasma sample spiked with Prednisolone and Metformin 
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Fig 4: Calibration curve of Prednisolone 
 
Recovery 
The recovery was evaluated by comparing response of 
extracted and un-extracted samples. The average recovery for 
Prednisolone in plasma was ranged from 72.2 to 77.6% for the 
low, medium and high quality control samples with an 
average of 74.2%. 
 
Stability Studies  
Stability studies were performed to evaluate the stability of 
Prednisolone both in aqueous solution and in plasma after 
exposing to various stress conditions. The stability studies 
performed include bench top stability, freeze thaw stability, 
long term and short term stock stability. Prednisolone was 
found to be stable for three freeze and thaw cycles. 
 
Table 2: Validation Parameters of Prednisolone by RP- HPLC 
method 
 
S. No Parameters Results 
1. Selectivity Pass 
2. System suitability Pass 
3. Accuracy & precision Pass 
4. Linearity Prdnisolone-R² = 0.999 
5. Recovery Pass 
6. Bench top stability 
 
Short term stock stability-
(2hrs,12hrs,24 hrs) 
Long term stock stability-
(10days,20days,30 days) 
7. Freeze thaw stability Pass (3 cycles) 
 
Conclusion 
The current validated bio analytical RP-HPLC method for 
Prednisolone offers good accuracy and significant advantages 
in terms of linearity, stability & selectivity. The separation 
method developed produce acceptable values of recovery. The 
chromatograms developed has well resolved peaks of 
Prednisolone without any interference. From the results we 
conclude that the developed method can be used in bio 
analytical, bioequivalence & pharmacokinetic studies with 
desired precision and accuracy. 
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